w ho annual report innovation dna always worked across disciplines geographies drive scientific discovery redefine possible improve patients lives working understanding diseases also world leader vitro diagnostics differ molecular level business track record allows us build lasting develop new tests medicines prevent meaningful partnerships across world diagnose treat diseases bring research academia public healthcare institutions patients need combined strengths diagnostics pharmaceuticals founding families continue hold majority p e n n n v n p r n e r personalised healthcare strategy aims fit voting stake company stability allows recently launched four new granted five breakthrough together partners right treatment right patient tradition sustainable thinking learn cancer treatments first therapy designations us made great strides overcoming setbacks focus lasting value patients cancer immunotherapy medicine food drug administration barriers healthcare developing worlds largest biotech company develop society remain dedicated highest tecentriq giving new hope medicines added nine local access plans fully breakthrough medicines improving standard standards quality safety integrity legacy people specific types key diagnostic instruments integrated local business care across oncology immunology infectious based respect individual well bladder lung cancer tests rich portfolio plans diseases ophthalmology neuroscience communities world live inroches global presence highlights redefining treatment oncology transforming laboratory work employees worldwide basel kaiseraugst switzerland cancer immunotherapy tecentriq available cobas e platform launched faster simpler mannheim penzberg germany bladder lung cancer laboratory testing read read north america europe employees employees recognised innovation managing rare blood disorder five breakthrough therapy designations granted potential new medicine emicizumab significantly reducing us food drug administration number bleeds group people haemophilia read read chugai tokyo japan partnering improve care contributing sustainability formal agreements signed several subsaharan roche ranked sustainable healthcare company hanghai countries improve access healthcare dow jones sustainability indices eighth year running china genentech san francisco read read usa asia key figures employees latin america employees chf million chf million africa australianew zealand employees employees group sales research development investments chf patients research development sites manufacturing sites dividend participating clinical trials pharmaceuticals diagnostics worldwide pharmaceuticals diagnostics worldwide million patients roche medicines roche group headquarters largest sites based number employees treated one top medicines list essential medicines research development sites pharmaceuticals diagnostics manufacturing sites pharmaceuticals diagnostics sales sites pharmaceuticals diagnostics number employees expressed fulltime equivalents growth rates report constant exchange rates cer average contents overview strategy market environment chairmans shareholder letter ceos shareholder letter business performance group performance pharmaceuticals performance diagnostics performance science innovation forefront finding cures cancer progress pipeline access healthcare complex challenge focus partnerships progress africa people developing leaders attracting retaining best talent safety health environment ensuring occupational health safety minimising ecological footprint community engagement providing longterm disaster relief investing education integrity business patient safety comes first matter engagement corporate governance board directors corporate executive committee remuneration report principles remuneration components roche reporting approach reporting approach roche reporting approach committed transparent reporting endeavour materiality accordance gri g guidelines drive economic social environmental performance material topics conducted materiality analysis corporate materiality level gathered input feedback rochecom diligence financial performance various internal external sources conferences drug efficacy safety counterfeiting materiality well regular interviews oneonone discussions biosimilar safety roche experts key stakeholders disease awareness treatment education key performance enabled us include topics stakeholder patient organisation support indicators reporting scope boundaries consolidated group risk report covers groups consider important business product portfolio strategy rochecom provide integrated information financial material risks discussed annually healthcare sector patient organisations patent policies performance online annual nonfinancial performance annual report corporate executive committee reviewed employees media investors payers regulators data transparency clinical trials report finance report well online report audit committee board directors governments rd pipeline strategy personalised rochecomar cover regions divisions january board directors effectiveness healthcare december risk management process regularly monitored final step combined various insights sustainable healthcare roche annual group risk advisory team overall identified material topics stood highly growth strategy emerging report pdf reporting scope defined outlined process reviewed externally appropriate relevant us key stakeholders developed markets rochecomarepdf finance report significant significant impact longterm success pricing changes scope compared risk management embedded levels employee engagement talent retention roche finance group pharmaceuticals diagnostics material topics reflected business executive compensation report pdf reporting accordance latest gri divisions global functions conduct formal priorities report content highlighted compensationbenefits rochecomfbepdf guidelines risk assessment process least year beginning chapter well aspect leadership commitments since followed gri g guidelines must develop risk plans material risks boundaries according gri organisational effectiveness gri g index global reporting initiative disclosure core group risk advisory facilitates risk discussions compliance rochecomgriindex application level also report number additional support business many specialist areas build concrete actions relating topics environmental responsibility indicators beyond requirements core level digital media security well compliance operational activities measure performance occupational accidents risk management listed online gri g index sustainability training sessions platforms defined indicators process community engagement rochecomrisk established help employees manage results materiality analysis endorsed supply chain management management risk management monitor mitigate risks appropriately roche corporate sustainability committee risk management policy sets approach chief executive officer identifying managing reporting internal read corporate governance external risks opportunities also identify see strategy business sustainability risks opportunities external assurance annual basis integrate existing current annual report includes independent risk management process assurance report nonfinancial reporting prepared pricewaterhousecoopers ag see independent assurance report roche sdgs sdgs roche increasing access healthcare supporting communities aim every person needs medicines support programmes result lasting improvements diagnostic tests able access benefit sustainable benefits communities operate hiv global access programme partnering started partnership maharishi institute international organisations offer sustainable solutions hiv viral south africa cover university education costs students load tests eligible low middleincome countries date futurelab genentech science education programme developed seven million infants tested partnership south san francisco unified school district signed memorandum understanding several countries support science education elementary school high school subsaharan africa help patients get better access healthcare contribution sustainability read access healthcare chapter read community engagement chapter committed sustainability years contribute number united nations sustainable fostering diversity inclusion meeting high standards business ethics development goals strive create work environment includes facets know integrity foundation business diversity license operate key ability make lasting impact public health pioneered programme providing opportunities highpotential september united nations general forefront developing effective women systematically acquire sponsorship valuable feedback roche supports respects human rights implemented human rights assembly unanimously adopted sustainable therapies diagnostic tools diagnose treat career progression protect respect remedy approach un human rights rochecom contribution development goals sdgs end poverty protect monitor cancer neurological disorders support international assignments one four councils ruggie framework humanrights un sdgs planet ensure prosperity part assignments developing regions employees complete mandatory training ensure understand rochecomunsdgs sustainable development agenda one objective sdg achieve universal health group code conduct including voice compliance agreement marked important milestone coverage prerequisite achieving better concerns business practices behaviour next phase sustainable development access safe effective highquality medicines engagement wide range stakeholders diagnostic tests developing innovative read people chapter read integrity business chapter approaches collaboration international committed supporting sdgs line local players strive break access business strategy particular sdg aims barriers many patients around world ensuring healthy lives promoting wellbeing supporting universal healthcare coverage goal beyond communicable diseases tuberculosis malaria noncommunicable diseases including next list selected examples cancer mental disorders also universally contribution number sdgs minimising environmental footprint recognised areas high unmet medical need aim minimise ecological footprint increase use renewable resources continuing expand global business goal reduce energy consumption compared levels also plan increase proportion sustainable energy compared levels read safety health environment chapter roche strategy strategy roche strateg focus finding new medicines diagnostics help patients live longer better lives evolve practice medicine focus people fitting treatments patients making mark guided purpose molecular biology seamless integration patients need next company year pharmaceutical diagnostics capabilities history advancing field medicine diversity approaches maximise innovation bringing novel treatments diagnostics patients longterm orientation patient remain core reason come work every day delivery create value stakeholders distinctiveness decisionmaking partner choice bringing significant medical excellence science accountable transparent benefit patients doctors payers offering great place work employees sustainable impact society creating topquartile total focus fitting treatments patients shareholder return investors providing right therapy right group people right time inhouse delivery structure combination pharmaceuticals diagnostics value stakeholders built innovation uniquely positioned deliver personalised healthcare also developing internal end takes people integrity courage capabilities building strategic partnerships passion make difference patients ready next stage personalised healthcare people proud say roche combine insights multiple data sources embrace diversity cultures people across sophisticated analytics drive effective group inclusive encourage efficient research allow better decisions richness ideas approaches brings patients decisionmaking principles processes continue concentrate energies emphasise transparent dialogue clear accountability entirely prescription medicines vitro encourage high degree empowerment diagnostics rather diversify sectors like generics overthecounter medicines structure built innovation autonomous medical devices research development centres alliances external partners foster diversity agility pursuit excellence science global geographical scale reach enables us distinctiveness rests four key elements bring diagnostics medicines quickly people exceptionally broad deep understanding need roche market environment market environment roche rapidly changing market environment beyond tablettowards digitisation life expectancy increased new medicines market time globally five yearsthe fastest increase since continued invest future yielded however healthcare quality improving five breakthrough therapy designations btds every year heart attacks kill seven million people quick accurate diagnosis make difference life death slowly cope ageing populations granted us fda medicines growing number patients one chronic alone established btd accelerates diseases light demographic changes development review medicines may leading healthcare company make decisive demonstrate substantial improvement existing preventive care also gaining importance testing options across stages treatment contribution higherquality diagnosis therapies achievements testify high leading increased focus diagnosis monitoring laboratory system generates wealth data allowing treatment breakthroughs biology technology level innovation pursuing research prevention technological advances drive physicians provide patients holistic accurate opening new ways improve save patients development activities together opportunities connect different instruments precise diagnoses well prevention lives even healthcare budgets increasing genentech chugai various external alliances platforms hospitals example need able treatment solutionsall faster pace pressure changing healthcare landscape offers reflect broad range approaches science connect devices healthcare solutions untold opportunities researchfocused healthcare centralised monitoring realtime data analysis addressing needs policymakers companies extensive knowhow environment changing rapidly new regulators challenges opportunities arise diversity roche well positioned capitalise technological debate access healthcare pricing regional gains average life expectancy years approaches ideas agility help us progress diagnostics pharmaceuticals reimbursement gaining momentum policy turn opportunities successes one roof enabled us leverage molecular discussions across world arrival highly years biology expertise future see us integrating effective hepatitis c medicines steady stream gaining knowledge data management realworld data creating insights targeted cancer medicines raising concerns scientific medical expertise critical data research development purposes affordability payers increasingly claim identifying effective treatment options modern support better treatment decisions patient funding challenges induced expensive innovative molecular diagnostic tools helped guide care rationale drives collaborations medicines soon become insurmountable appropriate therapy identifying specific drug foundation medicine flatiron health enabling targets body thus offering prospect us better leverage data advanced analytics governments responded challenges personalised healthcare digital revolution improve development medicines various ways many countries example africa america southeast asia europe potential transform healthcare therapy decisions patient care guidelines approval biosimilars outcome data clinical practice adopted discussion addition source oecd health glance increasingly digitised analysed addition latest advances diagnostics technology also growing number health technology regions defined world health organization existing data sets derived clinical trials working develop laboratory different assessment agencies around world assess development enables small patient groups instruments platforms connected evidence regarding clinical effectiveness safety translated knowhow number related specific therapy outcomes one single system enable vast set costeffectiveness medicines tests significant benefit patients result even effective treatment approaches healthcare system recently brought four world health statistics monitoring health sdgs rochecomvalueofinnovationstep frost sullivan healthcare medical device connectivity interoperability roche market environment market environment roche us remain key growth driver appreciate payers ask evidence number facilities help reduce operational us outperformed market growth patent cliff effectiveness new medicine complexity cost maintaining compliance pharma market growth pharmaceutical industry effectively manage potential budgetary impact order effectively meet increasing demand treatments might try address products deliver strong pipeline needs risksharing agreements addressing innovative new medicines expanding needs payers aim help patients gain access global biologics manufacturing network building maintaining trust stakeholders latest treatment options quickly time due lower capacity utilisation pharma industry faces challenges earning realigning small molecules network reflect trust particularly governments regulators improving productivity changing portfolio society large address challenges companies latest figures rd productivity suggest strengthening culture ethics integrity decline since late levelled us approvals new molecules past years adopting higher governance standards improving due largely stream promising relationships employees shareholders new molecules approved per year recent developmentssuch new technologies stakeholders better understanding biology disease significant increase data human health world north america europe asia pacific twenty years ago company operating isolation developments led scientific breakthroughs source ims midas could achieve great deal even previously intractable areas immuno future collaboration stakeholders within oncology cardiovascular disease hepatitis c diagnostics business china fact key beyond industry remain critical however concerns remain returns growth driver shift business opportunities success early research delivering drug development towards emerging markets whereas mature products increased collaboration various markets experienced slowing growth internal external stakeholders key one way increase productivity find new ways harnessing scientific technological advances perform expensive clinical studies decadesold key sustained growth pharmaceuticals improving rd productivity delivering pricing approach using phase ii iii clinical trials source cder nme bla filings approval fda website diagnostics alike people access new access solutions adapting evolving giving way cuttingedge study designs change medicines tests developed broad set regulatory environment pace drug development effectively sustaining economic growth initiatives improve patient access across allow evaluation promising compounds us remain key growth driver world include working governments recognition commitment specific patient populations forced set pharmaceutical industry despite recent slowdown disease awareness campaigns training lab technicians environment society roche named group right priorities shift resources products us market benefits structural characteristics sophisticated diagnostics training community leader sustainability within pharmaceuticals really impact patients lives also strive accelerated approval pathways large healthcare workers providing flexible pricing biotechnology life sciences industry dow agile decisionmaking roche teams growing population stable highquality solutions support payers reimbursement decisions jones sustainability indices djsi eighth come together look promising molecules infrastructure consecutive year different research organisations assess best way faster advance medicines key emerging markets may recording lower levels development process ultimately patients growth expected keep growing steadily benefit sooner china growing population access innovative medicines sustain market growth comes improving efficiencies notwithstanding geopolitical risks assuming consider rd productivity also continued access expansion refine manufacturing network optimal bcg perspectives onbcgcombiopharmardprod roche overview overview roche hon senator dr beth mugo kenya one tackle problem alone long went politics fighting kenya successful reducing toll economic social political rights communicable diseases aids tuberculosis disadvantaged kenya especially women malaria recent years though seen elected first female member parliament noncommunicable diseases cancer become nairobi represented constituency major killer personal story heightened years becoming senator awareness suffering caused cancer need take action party election joined government assistant minister education publicprivate partnerships essential address served minister public health healthcare issues complexity scope sanitation one top priorities kenya roche contributing sharing extensive improving maternal health establishing knowledge oncology helping improve patient health centres throughout country training access timely diagnosis treatment nurses able significantly reduce death rate women giving birth children everyone needs come together tackle disease five current first lady kenya taken established beth mugo cancer progress maternal care even foundation promote access information detection beyond zero campaign treatment breast cervical prostate cancer roche partnering us providing learned breast cancer research data basic training cancer support shock first instinct keep secret patient organisations links likeminded stigma associated disease international organisations kenya lucky tumour early stage could treated successfully took based kinds strong partnerships courage decided come forward story envision country healthcare accessible importance early detection generated affordable people well informed great deal media coverage followed upsurge health matters health sector women around country getting checkups serves public efficiently recalibrating healthcare priorities fight cancer working united nations development partners nongovernment organisations roche chairmans shareholder letter chairmans shareholder letter roche shaping future together focus innovative tests medicines enabling us play key role overcoming challenges facing global healthcare dear shareholders years decoding human challenges facing global health remain immense genome adoption united nations instance increase chronic diseases millennium health goals opportunities emergence new epidemics spread antibiotic challenges global healthcare greater ever resistance way achieve enduring solutions confident roche strengths adopt integrated perspective engage pharmaceuticals diagnostics well placed international multistakeholder collaboration actively help shape advance healthcare roche ready part committed innovation tomorrow united nations sustainable development goals health beyond spurred fact primarily due strong core business roche ranked sustainable healthcare still volatile environment impacted company dow jones sustainability indices austerity measures succeeded increasing eighth year running developing novel products remains way sales billion swiss francs address difficulttotreat diseases remains net income came billion francs greatest contribution society well way particularly proud many product launches create value consequently invest approximately make new treatments available various one fifth sales research development types cancer improve automate translated billion swiss francs create value vitro diagnostics dr christoph franz chairman board growth rates report constant exchange rates cer average roche chairmans shareholder letter chairmans shareholder letter roche light good fullyear results new medical technologies digitisation create technological possibilities global pressure imcore network partnerships huge opportunities us enormous scientific healthcare systems nevertheless call far foundation medicine flatiron health propose increase dividend chairmans video technological advances made development novel products projects kenya three examplesalbeit rochecom worlds major life science technology centres future vital treatments tests pivotal onesof wideranging activities th consecutive year archair pioneering spirit wealth ideas available patients need today external partners demonstrate way truly compelling regrettably variety reasons access approach opportunities challengeswith yet guaranteed everywhere openness team spirit tenacity roche part site together us shaping future means continuing many partners november instance set major task establishing maintaining look forward welcoming th annual develop product offerings markets globally imcore network academic institutions functioning healthcare system course general meeting roche holding ltd march entrepreneurial spirit sound strategic working roche advance research cancer responsibility individual state great many light companys good fullyear results instinct thanks go groups immunotherapies diagnostics also plays countries latest medicines diagnostic products board directors proposing dividend employees dedication crucial role search treatments tailored available everyone yet elsewhere even increase swiss francs per share nonvoting external partners willingness work patients individual immunobiology rudimentary healthcare resources lacking equity security subject approval roche towards shared goal patients wellbeing autumn travelled three subsaharan th consecutive dividend increase aim integrate diagnosis treatment countrieskenya nigeria cte divoire despite digital technologies applications even greater frequent absence basic necessities many places would also like draw attention changes would like thank shareholders extent clinical pictures treatment options including clean water infrastructure knowhow roche board directors professor pius baschera confidence us become ever numerous diverse see chronic illnesses roche teams field decided stand reelection way provide doctors patients working passionately local partners provide annual general meeting following ten years tenure comprehensive information aid decisionmaking treatments patients behalf board directors would like process partnerships entered extend sincerest thanks valuable foundation medicine flatiron health give certain achieve great deal contributions roches success us access data promising analysis tools collaboration governments patient groups field cancer roche developing aid organisations shown instance delighted able propose anita hauser pioneering solutions integrate interpret progress made kenya new oncology centres successful swiss business leader new member diagnostic data wide variety sources set agreement board directors vicechairwoman government training healthcare specialists board directors globally operating family enabling modern diagnostic tests cofunding business bucher industries ag anita hauser dr christoph franz developing pioneering solutions free breast cancer treatment patients public strong entrepreneurial background chairman board institutions regions countries interpret diagnostic data various endeavouring promote access healthcare means tailored local solutions sources roche board directors board directors roche board directors left right prof dr richard p lifton c e andr hoffmann vicechairman paul bulcke b e corporate governance sustainability committee representative shareholder group pooled b audit committee julie brown b e voting rights c e peter r voser c e c remuneration committee presidiumnomination committee prof sir john irving bell b e dr andreas oeri representative dr severin schwan f e nonexecutive director shareholder group pooled voting rights e f executive director bernard poussot c e prof dr pius baschera e committee chairperson dr claudia sssmuth dyckerhoff b e roche board directors december dr christoph franz chairman c e roche ceos shareholder letter ceos shareholder letter roche achieving medical breakthroughs saw important advances including regulatory approval first cancer immunotherapy medicine filing new treatment multiple sclerosis improving patients livesthis always ambition dear shareholders achieved financial targets drug administration something could pharmaceuticals sales diagnostics sales speed approval processes even increased well market growth roches business success reflected least diagnostics division also introduced number core earnings per share nonvoting equity key new instruments tests particular would product security increased like mention new immunochemistry platform cobas e new module clinical laboratories even important future product carry immunological tests per hour pipeline made good advances within enabling doctors make faster extremely reliable short period launched four new medicines treatment decisions pipeline made treat aggressive cancersskin cancer cotellic lung cancer alecensa tecentriq leukaemia venclexta complex highly innovative products bladder cancer tecentriq therapeutic developed people different disciplines areas filed marketing applications us business areas work closely together extend eu new medicine multiple sclerosis sincere thanks employees good advances ocrelizumab achieved positive latestage clinical outstanding achievements trial results new molecule emicizumab treats haemophilia bloodclotting disorder harnessing scientific excellence improve patients additionally five medicines granted lives possible help live longer breakthrough therapy designation us food goal drives us day day roche dr severin schwan chief executive officer growth rates report constant exchange rates cer average roche ceos shareholder letter ceos shareholder letter roche fight cancer latest advances made treatment multiple forefront cancer immunotherapy working closely payers service providers sclerosis ms highly encouraging ms ten investigational candidates currently already introduced flexible pricing solutions immunotherapeutic approaches ceos video autoimmune disorder immune system clinical development phase first several european countriesincluding different rochecomarceo attacks body data three largescale trials immunotherapeutic medicine tecentriq approved prices medicines used combination therapies combination therapies proving shown potential new medicine ocrelizumab us treatment bladder lung cancer versus monotherapies breast skin cancer highly effective even somewhat rarer representing first major improvement bladder countries initiated pilot projects promising form progressively deteriorating disease cancer treatment options years medicine collaborate setting necessary treatment found date also appreciably extends life expectancy people infrastructure andfor example uswe advancedstage lung cancer actively engage discussions payers new world leader oncology strive advance pricing models constant exchange rates planning new approaches better treat cancer cancer fact people respond differently medicines increase dividend swiss francs cells resourceful look ways circumvent remains huge medical challenge overall working governments payers treatment point time often begin immune system extremely complex aim goal ensure degree patient benefit roche strongly positioned future multiply latest immunotherapeutic keep cancer check effectively long innovation products taken account worlds largest biotech company leader approaches therefore proving promising termor even defeat itby using highly promising cancer therapy equipped one best help bodys immune system combinations complementary preparations expect witness market launches product pipelines industry number recognise fight cancer effectively example immunotherapeutic agents first biosimilars important laboratory diagnostics confident roche first time reason hope chemotherapies targeted antibodies medicines confident able continue year success story able cure patients advanced cancer tooor currently testing combinations meet challenge continually improving transform cancer chronic disease roche clinical trials standard care based strength developing combination therapies proven new compounds also view novel treatment thus newly launched medicines harnessing scientific excellence approaches strive flexible pricing important development business also models instead established practice pricing current year expect number key clinical improve patients lives possible medicines based vials miligrammes want study results product approvals overall link remuneration closely patient benefit anticipate sales grow low midsingle digit help live longer goal instance vary medicine constant exchange rates also aiming core dr severin schwan depending indication used earnings per share grow broadly line sales chief executive officer drives us day day roche combination roche corporate executive committee corporate executive committee roche corporate executive committee left right daniel oday dr stephan feldhaus dr sophie kornowskibonnet osamu nagayama ceo roche pharmaceuticals head group communications head roche partnering chairman ceo chugai roland diggelmann dr gottlieb keller dr alan hippe dr michael varney ceo roche diagnostics general counsel chief financial officer head genentech research early development gred cristina wilbur dr severin schwan prof dr john c reed head group human resources ceo roche group head roche pharma research early development member enlarged corporate executive committee pred roche corporate executive committee december roche business performance business performance roche bu sine pe r mance recently launched four new medicines strengthened leading position laboratory business time invested product pipeline among material topics covered chapter top investors rd across industries product portfolio strategy growth strategy emerging developed markets provide medicines diagnostic instruments different tests patients laboratories healthcare professionals roche business performance business performance roche g latin america sales advanced sales growth alecensa significantly reduced risk disease japan also led centralised worsening death compared crizotinib current point care solutions business standard care people alkpositive nsclc gazyvagazyvaro showed positive results high number launches pharmaceuticals major clinical trial gallium follicular lymphoma ood performance divisions roche recently launched four new medicines cotellic separate trial goya medicine diffuse large advanced melanoma alecensa lung cancer venclexta bcell lymphoma reach primary study goal chronic lymphocytic leukemia jointly commercialised abbvie tecentriq bladder lung cancer broadening diagnostics portfolio group sales rose chf billion despite perjeta actemraroactemra mabthera rituxan addition five fda breakthrough therapy designations roche added nine key instruments high investments launch new products japan sales grew despite biennial price granted roche medicines major tests comprehensive portfolio among new product development core eps grew faster sales cuts special price reduction rule bestselling highlight us launch roches cancer instruments cobas e immunoassay module core eps growth reflects good underlying medicines tamiflu alecensa actemraroactemra immunotherapy medicine tecentriq first coaguchek inrange system monitor vitamin k business performance impact changes key sales contributors international region fdaapproved treatment people specific type antagonist therapy accuchek guide next groups swiss pension plans ifrs net income sales gained driven asiapacific latin bladder cancer years furthermore generation blood glucose monitoring system constant exchange rates swiss francs america subregions us fda cleared tecentriq use previously treated metastatic nonsmall cell lung cancer nsclc fda approved two accompanying diagnostics sales pharmaceuticals division rose diagnostics divisional sales increased pivotal oak trial showed people form ventana pdl sp test complementary chf billion driven growth perjeta herceptin chf billionabove market growth centralised lung cancer received tecentriq live significantly diagnostic determines pdl status patients actemraroactemra partially offset lower point care solutions main contributor longer regardless pdl status compared bladder lung cancer cobas egfr sales pegasys tarceva lucentis led immunodiagnostics business receiving chemotherapy additional data mutation test v companion diagnostic lung presented ectrims congress september cancer medicine tarceva fda also granted us pharmaceuticals sales advanced led emea north america showed roches ocrelizumab increased disease premarket clearance clia waiver respiratory medicines xolair esbriet regions divisions largest markets sales control relapsing primary progressive cobas liat influenza ab rsv test first recently launched medicines tecentriq alecensa increases led centralised point care multiple sclerosis rms ppms roche seeking pointofcare test extends molecular testing contributed growth well sales eye drug solutions sales growth north america partially regulatory approval medicine rms liat system beyond influenza ab streptococcus lucentis cancer medicines avastin tarceva offset decline diabetes care business ppms us eu fdas action date include respiratory syncytial virus rsv fda declined due growing use therapeutic faced continued pricing pressure sales increase decision march also approved roche tests detection zika virus options europe sales growth driven asiapacific mainly driven china roche also presented important clinical results outlook pivotal study group people roche expects sales grow low midsingle key figures haemophilia showed prophylaxis digit constant exchange rates core earnings per emicizumab led significant reduction share targeted grow broadly line sales chf millions chf millions change change cer chf number bleeds time phase iii study constant exchange rates roche expects group sales chugai jalex found firstline treatment increase dividend swiss francs pharmaceuticals division diagnostics division core operating profit core eps diluted chf ifrs net income growth rates report constant exchange rates cer average ifrs international financial reporting standards formerly roche professional diagnostics europe middle east africa clia clinical laboratory improvement amendments european committee treatment research multiple sclerosis roche business performance business performance roche ales pharmaceuticals division increased especially china following approval lung increasing use people moderate progressive cancer indication sales us disease roche stepping efforts various chf billion driven growth breast cancer avastin already broadly used approved markets improve disease awareness inform indications declined largely due growing patients caregivers need early medicines actemraroactemra use new immunotherapy agents lung sustained treatment ipf cancer setting actemraroactemra rheumatoid arthritis herceptin perjeta kadcyla combined mabtherarituxan common forms gazyvagazyvaro chronic lymphocytic forms juvenile idiopathic arthritis increasing herpositive breast cancer herpositive blood cancer rheumatoid arthritis certain leukaemia cll rituximabrefractory follicular use actemraroactemra single agent metastatic gastric cancer herceptin herceptin types vasculitis sales continued rise despite lymphoma sales expanded us europe despite subcutaneous formulation remained key growth sales helped additional reimbursement competitive pressure increasing demand mainly increasing competition cll gazyvagazyvaro drivers globally approvals china continued growth us seen china us europe growth china approved cll countries due longer duration treatment combination supported expanded regional access largely following us eu approval medicine recently launched medicines perjeta perjeta sales advanced particularly diffuse large bcell lymphoma previously treated follicular lymphoma first alecensa people alkpositive advanced strongly europe us medicine half early uptake indication nsclc good uptake us sales approved use surgery early breast avastin advanced colorectal breast lung encouraging growth remained strong japan following fda pharmaceuticals cancer kadcyla sales fuelled increasing kidney cervical ovarian cancer relapsed approval tecentriq bladder lung cancer rochecom demand international region due mainly glioblastoma type brain tumour sales continued esbriet idiopathic pulmonary fibrosis market uptake us strong pharmaceuticals expanded access grow strongly international region ipf sales continued expand mostly due topselling pharma products chf millions mabtherarituxan avastin herceptin perjeta actemraroactemra xolair lucentis activasetnkase tarceva kadcyla oncology immunology oncology oncology oncology immunology immunology ophthalmology cardiovascular oncology oncology growth rates report constant exchange rates cer average roche business performance business performance roche europe eastern europe middle east africa eemea japan regional performance us good growth regions us europe latin america latam asiapacific apac us market continues area significant european market healthcare largely opportunity despite increasing complexity driven publicly funded continued face increasing demands rising competitive pressure dynamic regulatory strained healthcare systems despite european environment advances technology shift medicines agencys centralised approval medicines toward valuebased healthcare models navigate time european authorisation eemea latam apac canada form international region challenges remain focused delivering reimbursement continues vary country differentiated products working government spending levels healthcare stakeholders healthcare community created significant disparity access medicines differentiate products support physicians choices across eu part commitment accelerate ensure patients access medicines widen patient access medicines europe international expanding access medicines enabled us developed new pricing solutions give healthcare latam region experienced consistently achieve reimbursement several provinces china fda follows specific approval procedures systems flexibility making reimbursement high growth recent years resulting increased covering million people apac region medicines also created programmes decisions europe region contributed healthcare spending government attention contributed overall pharmaceuticals business expedite approval promising new treatments overall pharmaceuticals business delivered programmes improving access healthcare despite growth driven herceptin mabthera intended unmet medical need one growth driven perjeta actemraroactemra investments significant challenges remain rituxan avastin breakthrough therapy designation btd programme mabtherarituxan germany france italy including lack infrastructure trained received btds five indications largest contributors sales professionals low levels education awareness despite inherent volatility multiple barriers means awarded total btds since disparities local private public quality healthcare significant opportunities fda established programme japan healthcare systems across different latam growth development eemea region universal healthcare insurance system countries address issues roche collaborates drive access medicines aim implement fuelled strong sales new existing japan facing significant pressure reduce overall various partners help strengthen national tailored solutions middle east markets medicines us recorded yearoveryear medical costs addition general drug health plans hence increase access tests worked stakeholders adapt regulations growth accounts total price revision occurs every two years special medicines latam contributed overall local approvals based regulatory submissions pharma business half total sales marketexpansion repricing rule newly introduced pharmaceuticals business grew driven markets helps accelerate product attributed oncology medicines driven applied avastin given many patients still avastin herceptin perjeta sales growth registration timelines thus makes innovative part recent approvals tecentriq bladder receive adequate testing treatment chugai driven part inflationary price increases medicines available earlier patients one fda btds lung cancer alecensa lung cancer makes various efforts disseminate information argentina example patients emerging markets benefit focrorg also preparing potential fda approvals healthcare delivery different disease areas innovative medicines top products breakthrough medicines outside oncology including country chugai contributed overall challenging year apac region contributing regional growth avastin perjeta therapies ocrelizumab ms pharmaceuticals business sales increased due macroeconomic slowdown key kadcyla overall eemea markets contributed driven tamiflu alecensa actemraroactemra markets china taiwan focus pharmaceuticals business grew roche business performance business performance roche types multiple sclerosis ms disability disability disability time time time strong heritage relapsing ms secondary progressive ms relapses primary progressive ms secondary progressive ms without relapses progress oncology neuroscience people ms initially diagnosed relapsing ms rms time majority people rms progress secondary progressive ms source multiple sclerosis international federationtrojano et al transition relapsingremitting ms irreversible disability clinical evaluation neurol sci forefront finding cures cancer launched four new cancer medicines significantly years roche forefront improve patient outcomes tecentriq bladder lung developing medical solutions fight cancer cancer venclexta chronic lymphocytic leukaemia turning multiple sclerosis common form disease fu synthesised roches first anticancer alecensa lung cancer cotellic skin cancer central nervous system cns research long characterised clearly defined relapses drug inhibiting cell growth roches first history roche worlds first commercially often include neurologic symptoms less prevalent biotech product roferona approved major highlight us launch available benzodiazepine medicines librium highly disabling form disease primary treatment previously fatal form blood cancer first cancer immunotherapy medicine tecentriq valium invented roche scientist progressive ms ppms displaying steadily worsening cancer immunotherapy revolutionising way leo sternbach roches introduction two symptoms onset unlike rms last years roche brought new cancer treated proud among products major milestone impact approved treatments ppms medicines cancer patients longterm durable leaders field expect important data medicine still felt today remissions even cures possible specific many ten investigational cancer immunotherapy research advances led increase disease settings example herceptin shown molecules either monotherapy combination years later reached turning development newer efficacious treatments reduce number cases metastatic approaches end point understanding brain nervous however higher efficacy treatments typically positive breast cancer used early setting system leading tremendous opportunities accompanied higher safety risks people aggressive form lymphoma gaining regulatory approval medicines continue invest broad research development reason physicians patients cautious mabtherarituxan together chemotherapy mean patients need able receive programme focusing four disease areas using highefficacy treatments shown cure disease majority treatments immediately reimbursement negotiations patients however types healthcare infrastructure contribute psychiatric disorders including schizophrenia need highefficacy medicines offer cancer still significant progress needed delays numbering years patients access depression favourable safety profile currently seeking overcome challenge disease innovative new medicines many cases neurodevelopmental disorders including autism regulatory approval ocrelizumab first ms oncology prove late spectrum disorders downs syndrome fragile x treatment rms ppms ppms rochecom goal forefront finding cures neurodegenerative disorders including parkinsons would first treatment type oncology cancer demonstrated fact recently making many efforts accelerate access disease alzheimers disease disease pivotal rms trials medicine medicines around world one example neuroinflammatory disorders including showed high efficacy versus rebif interferon betaa personalised reimbursement models neuromyelitis optica multiple sclerosis ms twoyear period ocrelizumab demonstrated frameworks enable flexible pricing solutions favourable safety profile phase iii study key achievements oncology allowing medicines priced according ms particular significant advances data suggest ocrelizumab could potentially benefit deliver across different indications achieved fight disabling disease used earlier treatment pathway since neuroscience million cancer patients treated combinations provides flexibility past years numerous administered twiceyearly infusion offer people rochecom new cancer medicines recently introduced comes reimbursement decisions ensures timely treatment options available relapsing ms rms ms less frequent dosing schedule neuroscience fda breakthrough therapy designations granted cancer access innovative medicines patients medicines since weisgerberkriegl u et al estimation epidemiological effect trastuzumab years european countries j clin oncol sehn l gascoyne r diffuse large bcell lymphoma optimizing outcome context clinical biologic heterogeneity blood hauser sl et al ocrelizumab versus interferon betaa relapsing multiple sclerosis nejm online roche business performance business performance roche north america europe middle east africa emea japan ales diagnostics division grew strongly chf billion regions reported sales growth latin america asiapacific centralised point care solutions business grew supported tender wins largest contributor divisions sales many countries performance integrated serum work area solutions comprising immunodiagnostics tissue diagnostics sales increased sales divisions sales growth driven asiapacific region clinical chemistry segments advanced staining portfolio primary main drivers strong growth staining respectively companion diagnostics sales showed continued molecular diagnostics including sequencing strong growth regions contributed growth north america strong abovemarket growth sales increased virology portfolio increased access healthcare diagnostic performance driven laboratory businesses diagnosis monitoring hepatitis hiv diabetes care sales decreased predominantly solutions demographic shifts advances roche continues gain market share sales hpv human papillomavirus due continued price pressure us science technology led globally growing laboratory decentralised coagulation monitoring screening sales advanced blood screening volume tests leader field vitro segments important new business diagnostics roche well positioned benefit recently launched products diabetes care developments however public funding challenging market conditions continued impact constraints led consolidation laboratories regions overall performance topselling product portfolios chf millions hospitals number people diabetes continues grow along awareness asiapacific region major driver condition need manage adequate divisions growth immunochemistry key blood glucose monitoring systems contributor china generated absolute sales growth indeed markets within sales increase emea region driven region continued see volume growth core laboratory business contributions markets expanded access testing diabetes care sales varied due different levels market maturity stable economic developments africa major healthcare access programmes implemented number latin america business segments contributed cobas cobas cobas ventana accuchek local governments close collaboration growth sales expanding diabetes care immunodiagnostics clinical chemistry virology advanced staining diabetes care international organisations unaids partners industry roche supports several sales growth japan driven centralised initiatives sustainable commercial offers point care solutions tissue diagnostics overall diabetes care sales declined within however business diabetes care declined region however growth seen several markets formerly roche professional diagnostics growth rates report constant exchange rates cer average roche business performance business performance roche modern diagnosticsfaster simpler results accurate ever connected lab histopathology laboratories provides working increase efficiency exceptional staining quality connectivity laboratory solutions want modern connected lab provides interconnected instruments incomparable breadth menu allows fast results innovations support healthcare professionals new cobas integrated haematology analyser help take best patient decisions launched countries accepting ce mark fastest efficient way fully connected compared current methods innovative laboratory automated processing integrated automated system offers one streamlined solution broadening rich test menu streptococcus include respiratory syncytial workflows goal prepares stains analyses microscopy blood range new tests vitro diagnosis virus rsv infection rsv cause slides automation digitisation reduce need approved cleared regulatory authorities acute lower respiratory tract infections connected lab offers wider array tests resourceintensive manual microscope reviews certified launch new tests add infants one year age essential ever increasingly able deliver require less blood testing deliver highly comprehensive portfolios improving decision differential diagnosis rsv influenza results across different testing disciplines one accurate results faster making healthcare supporting laboratories ensure appropriate treatment soon onset blood sample thanks automated workflows efforts increase operational efficiency symptoms integrated solutions customers benefit coaguchek inrange system first fully interconnected instruments incomparable bluetoothenabled ptinr home health device june fda approved cobas egfr mutation ventana pdl sp test approved breadth menu fast highly accurate results gives patients healthcare providers greater test v use plasma samples companion fda complementary diagnostic provide pdl control coagulation status ability diagnostic nonsmall cell lung cancer nsclc status patients metastatic urothelial cancer newest member cobas modular monitor vitamin k antagonist therapy patient therapy tarceva first fda approval considering treatment fdaapproved analyser series cobas e module selftesting coaguchek inrange sets new liquid biopsy test aid clinical decisions immunotherapy tecentriq fda also approved immunodiagnostics represents major step forward standard care enabling providers monitor makes test fdaapproved companion test nsclc realising connected lab first launched patient ptinr data reducing visits lab diagnostic detection epidermal growth module designed maximum consolidation factor receptor egfr gene dna derived new menu zika testing enables healthcare high throughput continuous operation accuchek guide nextgeneration blood plasma tumour tissue professionals quickly diagnose infection simultaneously reducing amount waste glucose monitoring system launched first virus helped prevent units blood generated new system doubles currently countries designed make everyday august fda granted premarket clearance infected zika virus released blood available immunochemistry testing capacity blood glucose monitoring easier provides k clearance clia clinical laboratory transfusion patients puerto rico floor space requires low sample advanced accuracy reliable diabetes management improvement amendments waiver cobas fda granted approval cobas zika assay volume delivers fast reliable consistent supports people diabetes reducing time influenza ab rsv test use cobas liat investigational new drug application protocol highly accurate patient results spend thinking daily therapy system first pointofcare test extending issued emergency use authorisation routines simplifies blood glucose monitoring molecular testing beyond influenza ab lightmix zika rrtpcr test fully automated system ventana improves testing experience system primary staining improves workflow prothrombin time pt international normalised ratio inr assays evaluating extrinsic pathway coagulation piedimonte g et al respiratory syncytial virus infection bronchiolitis pediatr rev products may available markets roche business performance business performance roche cervical cancer screening diagnosis womens health screen manage diagnose identify women risk identify women require intervention identify women treat secure health avoid disease cobas hpv test cintec plus cytology cintec histology product portfolio provides women women test positive genotypes hpv important fertility marker used assess ovarian health problems pregnancy hyperglycaemia physicians additional insights critical health hpv high risk developing precancer reserve levels elecsys amh test simple blood properly managed result birth issues allows informed decisions cancer women carrying one test performed day complications affect mother child precise steps prevention early detection highrisk hpv genotypes lower risk menstrual cycle accuchek diabetes management solutions offer therapy every stage womans life developing precancer cancer would require accurate reliable blood glucose monitoring systems followup test prevent unnecessary treatment preeclampsia serious pregnancy complication diabetes management software solutions education cancer example biomarkers provide vital costs healthcare systems cintec plus usually occurring weeks pregnancy programmes along healthy diet moderate information tumours structural cellular cytology test addresses issue backed landmark one leading causes death complications exercise necessary insulin therapy tools genetic makeup well subtype together studies palms test uses mothers unborn babies help keep blood glucose levels healthy range physical characteristics tumour dualbiomarker technology simultaneously detect treatedthe cure delivery baby biomarkers facilitate decisionmaking guide two specific biomarkers p ki elecsys sfltpigf immunoassay ratio test predicts portfolio also comprises tests identify infections therapy selection early intervention also critical strong indicators presence transforming rules shortterm risk developing microorganisms including toxoplasmosis upon initial diagnosis breast cancer fiveyear hpv infection thus identifying women disease women suspected preeclampsia syphilis causing treponema pallidum hepatitis b relative survival rate women stage cancer benefit immediate intervention e parvovirus rubella cytomegalovirus herpes compared stage foetal genetic conditions identified based simplex others represent high risks cintec histology test supports confirmation foetal dna circulation pregnant womans pregnancy newborn child early diagnosis cervical cancer screening diagnosis cervical disease actually present based blood harmony prenatal test new type initiation medical intervention critical cervical cancer become one preventable p biomarker guides pathologists screening test analyses fragments dna mother child forms cancer thanks implementation identification highgrade cervical disease tissue pregnant womans blood sample assess probability screening vaccination programmes hpv biopsies may missed standard morphologic several genetic conditions including trisomy maintaining wellbeing women known cause cervical cancers interpretation alone moreover test syndrome trisomy edwards syndrome following menopause disruption balance roche cervical cancer portfolio advances current recommended medical societies trisomy patau syndrome test non bone breakdown new bone formation screening diagnostic approaches medical diagnosis cervical disease becoming global invasive highly accurate doctors much cause women lose bone faster rebuilt value hpv screening well established globally standard care less likely recommend invasive followup testing bones become brittle easily broken countries started adopt hpvbased primary amniocentesis due false positive results menu bone tests provides earlier screening approaches leading dramatic increase key information pregnancy complete assessment osteoporosis therapy efficacy screening effectiveness supported data average age firsttime mothers rising gestational diabetes high blood glucose bone mineral densitometry tests alone landmark athena clinical study cobas hpv fertility rates declining thus increasing hyperglycaemia among common diagnostics test currently first fdaapproved hpv need information supports family planning rochecom test use hpv primary screening women natural conception artificial reproductive diagnostics aged older technologies antimllerian hormone amh parker js mullins cheang et al supervised risk predictor breast cancer based intrinsic subtypes j clin oncol national institutes health seer statistical fact sheets globocan estimated cancer incidence fact sheets wright tc et al athena human papillomavirus study design methods baseline results j obstet gynecol ikenberg h et al j natl cancer inst human papillomavirus hpv cervical cancer fact sheet zeisler h et al predictive value sfltplgf ratio women suspected preeclampsia n engl j med roche business performance business performance roche dr thomas wright professor emeritus columbia university translating research clinical practice entered medical school planning fulltime could translate clinical practice research quickly realised becoming changing fdaapproved procedures cervical pathologist could combine research clinical cancer screening requires clinical trials scale practice turning point career academic institution could afford right moment partnership roche decided conduct ive always loved contact patients helped athena trial patients understand emotional impact women gave opportunity participate worked anxiously awaiting results screening talented people roche design study cervical cancer importantly also gave protocol analyse clinical findings present clinical experience needed help develop national results regulatory authorities guidelines managing treating disease fda approved roche hpv test year career standard screening primary screening us sure pap test dramatically reduced number paradigm shift save many lives deaths cervical cancer us developed countries studies shown however addition new screening technology half women highgrade cervical physicians effective cervical cancer cancer precursors pap test misses disease vaccine young women targeted molecular therapies incredible think could scientists discovered hpv causes practically eliminate disease next two almost cervical cancers two types decades many countries responsible cases breakthrough opened exciting new horizons terms years collaboration roche prevention treatment detection patients impressed knowledge dedication clinicians people welcomed input academic world treated trusted partner trustful partnership academia industry partnership continues collaborating advances molecular screening technology followed roche evaluating biomarkers play including roche diagnostic test reliably detect role cervical cancer give us added precision dna two aggressive strains hpv detecting treating disease early stage roche science innovation science innovation roche sc ie nce innovation material topics covered chapter product portfolio strategy rd pipeline strategy personalised healthcare scientists understanding disease factors influencing drug response critical latest technologies contribution un sdgs provide unprecedented insights scientists analyse discuss impact new drug candidates based digitised test results roche science innovation science innovation roche w e embracing best technology partnerships leverage power unique pharmaceuticaldiagnostic structure advance science develop new therapies roche generated breakthrough insights turning todays science tomorrows cures developed products transformed medical continue help define future medicine latest researchsupporting technologies leadingedge data science allow unprecedented insights root causes diseases parallel digitisation data care people difficulttotreat deadly unprecedented opportunity match right enables experts discuss study results new drug candidates colleagues across globe real time diseases building legacy embracing treatments right patients nonsmall cell lung best technology partnerships leverage cancer nsclc instance used considered one power pharmaceuticaldiagnostic structure disease know dozen genetic alterations cause nsclc range medicines generation targeted medicines diagnostics forefront finding cures cancer precise diagnostic tests combination therapies available specifically target alterations patients well answer hard questions arising approvals monoclonal antibodies mabthera allow millions people instance hiv enough understand underlying personalised healthcare front rituxan herceptin opened door new infections live golden years likewise biology alone addition variations genetic paradigm mean clinical development cancer care landscape since molecular herceptin one first manmade antibodies code studying genes get switched production patients daytoday lives insights expanded exponentially long ago approved late changed treatment also learning therapy cancer biopsies tested single biomarker landscape herpositive breast cancer turning impacted patients particular immune response research may complex processes capability screen blood tumour deadly disease one eradicated even differences way individual challenging never lose sight fact tissues hundreds genetic alterations treated early stage metabolises medication increasing granularity reason come work help patients parameters seeing mutations differ demonstrates exponential possibilities drug built strong rd capabilities address medical need patients diagnosed cancer new tests cancer screening early diagnosis discovery development enable physicians oncology immunology inflammation infectious also within individual patients tumour addition breakthrough therapies leading previously design treatment regimen personalised diseases neuroscience ophthalmology remain know tumour development growth unimagined outcomes cervical cancer third patients needs optimised efficacy safety open areas including debilitating deadly intricately intertwined environment common cancer women leading cause inherited genetic diseases make real tumour cells reside well way immune cancer death worldwide good example advance science cancer immunotherapy difference patients many children system responds cancer short tumours progress made fighting cancer today cervical cit roche launched imcore global network focus diseases complex complex structures designed evade natural cancer nearly avoidable thanks vaccination leading cancer immunotherapy centres excellence continually raise bar rd projects defence mechanisms screening diagnosis treatment human goal imcore facilitate access new successful fact majority efforts papillomavirus hpv infection primary cause technologies emerging data among top result viable drugs studies lead technology advantages roche offers leading portfolio tests screening researchers around world within network approval still benefit represent investing heavily novel tcell bispecific diagnosis hpv basic clinical scientists work together learning opportunities bring us closer solving antibody tcb platform generating inhouse roche scientists goal developing potential mysteries disease despite challenges engineered powerful anticancer antibodies designed ophthalmology introduction lucentis cures people cancer continue invest heavily take bold risks remain physically link immune cells cancer cells one completely changed space restoring relentless pursuit innovative therapies two parts bispecifics bind cancer cell improving vision patients destined go blind roche invests chf billion research stateoftheart diagnostics transform patients lives another part connects immune cell allowing development rd per year bring next unaidsorgenresourcesfactsheet cdcgovcancerinternationalstatisticshtm iarc globocaniarcfroldfactsheetscancerscervixnewasp roche science innovation science innovation roche patients metastatic breast cancer immune cell move attack innovative oak trial showed significant improvement case inflamed tumours immune cells called bispecifics allow immediate scalable dose overall survival compared chemotherapy tlymphocytes found already present survived months controlled approach harness immune system people recurrent nonsmall cell lung cancer tumour microenvironment goal use cancers also suitable combination failed chemotherapy also announced positive medicines checkpoint inhibitors eg tecentriq months therapies strategy explore multiple bispecific results pivotal phase iii gallium study investigational molecules antitigit formats identify maximise clinical benefit anticd drug gazyvagazyvaro previously unleash tumour resident tcells attack kill patients anticeacd tcb rg untreated follicular lymphoma common cancer cells case immuneexcluded tumours first tcell bispecific developed roche enter form nhl study challenged tcells able recognise tumours invested powerful resources diagnostics clinical trials assessed solid tumours going headtohead revolutionary able infiltrate tumour microenvironment clinical trials realworld data work seamlessly two different anticdcd bispecifics different anticd drug mabtherarituxan achieving exert anticancer immune response scenario real time enhance organisations learning formats rg rg studied prolonged disease control chronically relapsing looking combinations tecentriq loop driving innovation laboratory treatment bcell malignancies non form lymphoma gazyvagazyvaro new targeted medicines avastin cotellic clinic back ultimate goal hodgkin lymphoma nhl landmark provides hope clinical benefit well investigational molecules antitgf revolutionising ways personalise patients around world drive tcells tumours cancer treatments providing subgroups patients several types cancer cit rapidly improving therapies specifically designed treat standard care yet despite years progress combination ambush tumours found immune deserts cancer rich pipeline poised cancer remains devastating disease almost combination therapy nothing new oncology tcells present aim redirect make dramatic progress area next million people diagnosed cancer half century patients treated engage tcells use tcelldirected decade addition clinical diagnostic nine million people died cancer even mortality simultaneously different chemotherapeutic agents bispecific antibodies investigational technology experts developing industryleading rates falling many cancers burden drugs new precision drug rg personalised cancer vaccines platform uses cuttingedge imaging science disease increasing around world due ageing targeting combination treatments alternatively addition tcbs testing look inside tumour see effect new drugs populations environmental factors launch multipronged attack molecular molecules cergutuzumab amunaleukin patients teams digitise integrate remain committed sciencedriven research causes cancer viral diseases taught us rational ceailv fapilv rg interpret complex data generated drive better unlock biological mechanisms enabling us treat combination therapies needed simultaneously tumourtargeting antibodies carrying engineered decisions drug development increasing numbers cancers address drug resistance hit multiple mechanisms viruses use spread variant tcell growth factor interleukin il achieve longterm survival search resist treatment applies cancer antibodycytokine fusion proteins stimulate extending expertise haematology potential cures recent research human immunology tumour proliferation tcells tumours also learned much nuances blood biology led innovative approaches treating studying anticd monoclonal antibody rg cancers studying millions patients hitting cancer hard cancer harnessing power immune system order prime andor activate tumour antigen pioneered science led mabtherarituxan currently molecules one exciting approaches ability specific tcells providing help continue investigate venclexta breakthrough clinical development oncology clinical studies understand best characterise known types need types immune cells called antigen therapy codeveloped abbvie approved currently ongoing tecentriq either human cancer three primary immune presenting cells apcs antiox antibody also fda early later year eu monotherapy part combination therapy phenotypes inflamed tumours immuneexcluded primes tumourfighting tcells get started treatment patients chronic lymphocytic trials address diversity types cancer tumours immune deserts phenotypes journey attacking cancers simultaneously leukaemia cll exploring molecules including lung colon gastric ovarian breast kidney describe tcells immune system interact inhibiting immunosuppressive cells called regulatory advance treatment blood cancers including bladder lung cancer claims lives tumour classification system allows tcells tregs finally molecules tcell bispecific antibodies anticdcd oral research day leading cause cancer death us better determine appropriate treatment emactuzumab removing immunosuppressive small molecule activator tumour suppressor p development globally developing tecentriq combination combination strategies based individuals cells tumour microenvironmentin idasanutlin antibodydrug conjugates polatuzumab rochecomresearch chemotherapy address need treatment immune biology ensuring best chance case tumourassociated macrophages tams agents anddevelopment announced results tecentriq phase iii effective antitumour immune response example american association cancer research aacr cancer progress report clin cancer res slamon et al n engl j med swain et al n engl j med roche science innovation science innovation roche recently gone beyond blood cancers improve core social communication social novel compounds pain targets nav antibody developed collaboration chugai leveraging insights blood cell biology haema interaction deficits potential could yield nonopioid based mechanisms treat pain entered phase complement system tology benefit patients nonmalignant blood first treatment core symptoms asd key innate immune defense mechanism study disorders active preclinical clinical programmes digital biomarkers derived data generated potential enhanced antibody within underway haemophilia polycythaemia studying two latestage molecules crenezumab consumer devices smartphones wearables broad range complementmediated diseases vera paroxysmal nocturnal haemaglobinuria gantenerumab monoclonal antibodies potential increase precision clinical betathalassaemia haemophilia rare genetic different modes action designed tackle decisionmaking even predict disease course asthma began phase ii trial firstin disorder example unblinded phase iii study amyloid plaque build brain researchers developed suite smartphone class antibody inhibits binding interleukin showing statistically significant reduction alzheimers disease patients using unique assessments allow continuous monitoring st receptor pathway thought number bleeds time people treated expertise diagnostics develop new tests assist symptom fluctuations across number neurological involved variety lung ailments st emicizumab prophylaxis compared receiving clinicians diagnosing alzheimers conditions including parkinsons disease ms antibody inlicensed amgen potentially offers prophylactic treatment assessments complement conventional gamechanging treatment patients severe psychiatric disorders testing selective physicianled assessments limited asthma innovative multipronged study also neuroscience inhibitor subtype gammabutryic acid availability expert centres resourceintensive exploring biomarkers associated asthma invention telescope opened receptors cognitive impairment associated represent snapshot time chronic obstructive pulmonary disease copd previously mysterious universe advanced imaging schizophrenia randomised clinical trials technology allowed us unparalleled access also began earlystage clinical studies novel immunology inflammation infectious diseases promising candidates rich antiviral workings human brain turning compound trace amineassociated receptor developing medicines area immune pipeline treatment hepatitis b virus hbv point understanding biologic mechanisms taar partial agonist pdea inhibitor mediated diseases treat number illnesses infection including directacting antivirals underlying pathology nervous system disorders treatment negative symptoms schizophrenia including rheumatoid arthritis ra systemic lupus immunomodulatory molecules consider one strongest pipelines industry early clinical studies roche first company erythematosus sjgrens syndrome novel synergistic combinations two cornerstone roche developing medicines range serious identify characterise taar family brutons tyrosine kinase inhibitor btki mechanisms key approach achieving neurological diseases including alzheimers disease receptors starting back blocks bcell signalling resulting excessive functional cure hbv molecules include first parkinsons disease pd huntingtons disease forefront development selective taar immune response seen autoimmune diseases viral rnatargeting compound early development autism spectrum disorders asd multiple sclerosis agonist compounds studied ambitious phase ii trials ra invented inhouse comprises locked nucleic acid ms schizophrenia spinal muscular atrophy lupus ra trial innovative sevenarm lna chemistry gained acquisition sma also working regulators initiated two phase ii trials sma oral study headtohead comparison current santaris pharma novel lna platform payers concerning new trial designs new molecule offering novel mechanism action mrna standard care also initiated phase ii trial allows access previously impenetrable pathways endpoints order support approvals disease splicing modulator tackling debilitating ra cadherin antibody believed disrupt across many different diseases attacking disease modifying medicines eventually fatal genetic neuromuscular disorder tissue cell interactions drive inflammation targets level rna rather protein common geneticallybased causes nonimmunosuppressive manner addition began asd continue invest heavily novel infant death amyotrophic lateral sclerosis als phase ii study treatment sjgrens syndrome antibacterial resistance focusing novel vasopressin va receptor antagonist may progressive neurodegenerative disease also known illness approved treatment one targets novel approaches developing antibiotics lou gehrigs disease began earlystage study common rheumatic autoimmune diseases aim curing severe multidrug resistant novel molecule believed inhibit pathway leading internally discovered cathepsin inhibitor designed bacterial infections nextgeneration betalactamase advances imaging technology enable neuronal cell death implicated als roche also interfere specific immune pathway dysregulated inhibitor nacubactam broadspectrum antimicrobial working find medications chronic pain multiple autoimmune diseases time activity combined betalactam antibiotics us better understand biology increased potency improved safety limit leaving intact pathways immune system dual mechanism action effectively inhibiting addiction seen current therapies collaboration involved example fighting infections wide range betalactamase enzymes responsible nervous system disorders xenon pharmaceuticals continue develop humanised complement inhibitor c monoclonal antibiotic resistance also inhibiting certain bacterial roche science innovation science innovation roche pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammation immunology cell wall enzymes compound currently learning moving faster leading phase development granted fda fast way smarter drug development track designation part recent collaboration neuroscience agreement us biomedical advanced research nature personalised healthcare means development authority barda patient populations becoming smaller treatments growing nuanced continuing ophthalmology feedback loop dependent confluence science infectious diseases highly innovative bispecific monoclonal anti data access data ever vegfang antibody rg already research development clinical trials investigation wet agerelated macular degeneration advanced genomic sequencing modern diagnostics entered phase ii study diabetic macular oedema testing well realworld sources like electronic ophthalmology twopronged drug developed proprietary medical records patient registries window crossmab technology binds vascular endothelial collective experience patients around growth factor vegf one arm bispecific world adds significantly knowledge allows others monoclonal antibody angiopoietin ang us build decades also lampalizumab understanding disease core unlocking phase iii studies geographic atrophy power data setting industry precedents ensuring quality validity consistency pipeline new molecular entities nmes covers broad range diseases highly innovative technologies applied create produce active molecules inherited genetic rare diseases numbers brackets referring personalised healthcare projects included diverse technologies inventing molecules internal experts external partners medicinal properties believe make pioneering new approaches biomarker analysis difference patients certain inherited genetic modern safety assessment approaches nextgeneration diseases sometimes known rare diseases many sequencing artificial intelligence advanced cases inherited genetic diseases manifest analytics bring us holistic understanding innovating clinical trials feed back refine trial better identify infancy childhood leading childhood debilitation data thus affording deeper faster decades development activities drugcentric potential drug combinations immunemediated early death urgent need develop insights science telling us approach focused proving clinical benefit onesizefitsall diseases using multiindication approach therapies patients often limited combines knowhow immunology genomics medical landscape science patientfocused allows us see early signs efficacy available treatment options sma huntingtons create database information immune strive move drug development study compounds cathepsin inhibitor disease examples inherited genetic diseases cells accessible researchers direction precision targeting example tested treatment sjgrens currently developing candidate generating exciting crosspollination collaboration medications diagnostics identify subgroups syndrome parallel small number therapeutics collaborative partnerships among scientists working overlapping pathways patients particularly cit demands raise patients celiac disease believed targets researchers working cancer immunotherapy bar clinical trial designs creating similar immune principles apply smart agile product development cit instance trying turn immune studies simultaneously test single drug multiple pace progress medicine offers new hope system studying rheumatoid arthritis diseases test several drugs single disease furthermore decisions drug development patients delivering next wave paradigm autoimmune diseases seek dampen immune condense traditional threephase clinical increasingly reflect voices patients shifting therapies faint heart requires response shared insights valuable trials fluid adaptive process efforts allow paperwork protocols dosing delivery whole new approach developing drugs teams addition benefits database us develop bring right safe medicine method proactively introducing perspective breaking new ground novel technologies integrates internal data data generated right patient efficient manner cit core heart work cuttingedge analytic capabilities leverage external experts example piloting sophisticated trial design biweekly visits doctors office example pipeline combined strengths pharmaceuticals diagnostics features continual evaluation array data patients sma als going hardship rochecompipeline roche science innovation science innovation roche preferable subcutaneous intravenous creating value transformative partnerships neuroscience roche signed license agreement antibacterial resistance ten million people intramuscular injections know challenging roche long valued external innovation chugai sa antiil receptor monoclonal projected die untreatable bacterial infections patients sma als participate clinical critical component rd strategy significant antibody currently investigated two pivotal roche leveraging decades infectious trials designed studies devastating proportion sales driven products born phase iii studies neuromyelitis optica spectrum disease research help address threat teams diseases using valuable input patients research partnerships current disorders nmosds rare autoimmune disease pharmaceuticals diagnostics divisions caregivers similarly collaborating closely pipeline comprises partnered products central nervous system characterised mainly embarking landmark alliance us patient associations alzheimers disease asd ever collaborations critical realise inflammation optic nerve spinal cord authority barda involves studying next neurological disorders study novel treatments potential personalised healthcare well enhance approved therapy nmosd generation betalactamase inhibitor potentially areas lucentis current standard pipeline key disease areas exceptional often confused multiple sclerosis time breakthrough antibiotic cure drugresistant severe care many retinal diseases exploring alliances across therapeutic diagnostic diagnosis sa offers potentially bestindisease infections well vitro diagnostics capabilities innovative delivery mechanism would alleviate technological areas helping us better understand treatment nmosd adds growing portfolio burden patients must visit doctor leverage complex biology find new drug candidates treat people neuroinflammatory disorders oncology increasingly collaborating regular intravitreal injections make best use growing volume genomic external partners particularly cancer immunotherapy realworld data immunology research around role explore drug combinations rationally realworld considerations innate immune response triggering autoimmunity designed maximise therapeutic benefit along clinical superiority also demonstrate partnering roche builds culture one growing area interest roche tailored biology associated patients tumours value products everyday settings listen carefully potential partner entered early rd collaboration monash entered ten new clinical collaboration realworld considerations increasingly important creatively structure collaboration meets university melbourne australia focus agreements develop lead immunotherapy drug ensuring products accepted national parties needs choice driven searching novel innate immunity checkpoint modulator tecentriq broad number haematological policymakers adopted medical practice partners share passion innovative discovered monash principal investigators solid tumour types addition announced dimension adds development complexities science look opportunities address unmet considered leaders space antist collaborations biontech germanybased large proportion drugs pipeline medical need potential revolutionise investigational medicine inlicensed amgen biotechnology company develop manufacture instance developed sophisticated standard care also keep finger complements existing rd programmes commercialise novel messenger rna mrnabased treatment schedules advanced diagnostics pulse emerging science alliances strengthens respiratory portfolio antist individualised cancer vaccines hanmi needs done countries radiation leading academic entrepreneurial investigators potential best class patients established innovative drug company korea devices cooling apparatus laboratory capacities whether small large value partnerships equally highneed asthma chronic obstructive pulmonary develop novel panraf inhibitor accommodate specific needs different disease well ilmediated diseases countries subtle treatment variations major entered number transformative academic alliances working economic disparities making great strides partnerships also entered option agreement distinguished scientists cuttingedge projects understanding medical care delivered across novimmune ni antitlr tolllike leading institutions harvard university globe ensure medicines ophthalmology new alliances helping extend receptor investigational medicine advances massachusetts institute technology cambridge deliver tangible benefit patients worldwide scientific leadership retinal diseases signed scientific understanding cellular molecular university max planck institutes swiss federal license agreement eleven biotherapeutics immunology guiding development potential institute technology collaborations cambridge us novel antiil monoclonal new treatments believe ni potential seek find develop new molecules invent new partnerships help us stay front line antibody combination standardofcare bestinclass therapy treatment research tools advance understanding antivegf therapy positioned firstinclass rheumatoid arthritis autoimmune diseases disease mechanisms innovation treatment wet agerelated macular degeneration diabetic macular oedema amrrevieworg roche science innovation science innovation roche dr amy abernethy flatiron health advancing cancer treatment together cancer researcher clinician caregiver capturing data million unique vantage point fight cancer patients cancer care providers opens years worked practicing oncologist new vistas physicians scientists spent much career duke university partnership roche helping us accelerate last served professor medicine head programmes addition collaborating cancer care research program joined designing clinical trials promising new flatiron health saw opportunity make cancer treatments profound difference bringing together fields medicine technology roche flatiron share vision personalised healthcare resonates secretary flatiron founded premise leveraging board personalised medicine coalition big data help researchers discover effective flatiron also works roches strategic partner therapies better match cancer patients foundation medicine analyses variations lifesaving treatments human genome find targeted cancer therapies next step collaboration truly exciting gleaning insights realworld evidence combining realworld evidence genomic analysis today cancer patients us cancer patients learn therapies work best enrolled clinical trials data individual principle source analysing treatments effective well providing clues physician always come back human developing future therapies impact work one patients lost patients cancer undergoing battle skin cancer asked use insights treatment without access clinical trials tumour tissue family history melanoma treatment help others owe flatiron focuses cancer patients many patients make best use pearls capturing realworld data information left behind oncocloudtm platform help trained experts take unstructured data medical daughter know well limits case notes xrays pathology reports todays medicine father suffering transform validated information extremely difficulttotreat cancer video registry strict procedures ensure underscores urgency everything rochecomarbio quality entries patient anonymity find effective oncology treatments roche access healthcare access healthcare roche acce material topics covered chapter healthcare growth strategy emerging developed markets sustainable healthcare pricing disease awareness treatment education design access programmes country level support healthcare systems improve diagnosis educate build contribution un sdgs local skills address affordability issues measuring blood glucose levels highest degree accuracy precondition managing diabetes successfully roche access healthcare access healthcare roche g round breaking advances medical science meaningful reach patients today million people across globe making progress long way go lack access essential healthcare services access really make difference ground need disease awareness modern tools reliable fast diagnosis key factors successful medical interventions healthcare one biggest challenges society deep understanding challenges facing one work partnership individual healthcare system take systematic address multidimensional challenge improving comprehensive approach identifying key one aspect healthcare often enough especially hurdles right stakeholders order develop million people country reduction like live disease challenges patients treatment complex diseases like cancer access tailored effective solutions reach patients average timetotreatment families facing role diagnostics hospital cancer patient beneficial partnerships broad spectrum stakeholders treatments play managing disease aim trained oncologist turn access diagnostic essential improve access healthcare people awarenessa crucial factor success support voice patients foster constructive test disease effective accompanied need date developed access plans awareness disease symptoms essential healthcare debate education awareness total clear proposal overcoming access screening early detection support barriers within particular country plans major focus connecting countries patient organisations represent patient views believe responsibility improve access integrated local business ensuring continued best practicesharing found example issues surrounding healthcare including timely need working together sustained support thus demonstrating ongoing people philippines dealing equitable access treatment help shape partners resources world commitment markets integral part similar issues people venezuela current future healthcare environment making ability help facilitate change business model different geographies unaware patients voices heard strengthened commitment widening access others approach held first ever summit industry partnership access accelerated access healthcare complex challenge dedicated developing sharing access best practices exchanging knowledge ideas brings together biopharmaceutical companies believe four key factors need place across globe find best way promote th annual international experience exchange leverage innovation expertise resources successful treatment awareness diagnosis healthcare access programmes collaboration across patient organisation ieepo large global patient address treatment noncommunicable diseases capacity funding wide array different geographies similar hurdles virtual organisation meeting fully sponsored roche ncds diseases cancer heart initiatives support four areas improve access community shared questions ideas held copenhagen denmark march disease significant growing problem low medicines tests include working developed online case study library greatly overarching theme innovation record total lowmiddle income countries nearly governments disease awareness campaigns training support implementation local access plans delegates countries attended ieepo deaths kinds diseases occur access lab technicians sophisticated diagnostics training coming years accelerated multiyear programme facilitating community healthcare workers providing flexible four key factors need place cooperation healthcare stakeholders pricing solutions patient organisationsvital partners achieve tangible impact improving access patients patient organisations essential successful treatment awareness diagnosis treatment care ncds thanks argentina comprehensive local programme partners roche share common vision focus diagnostics medicines well implemented led expansion improve patient access innovative treatments healthcare capacity funding healthrelated data expertise across oncology treatment coverage approximately one services help us understand range areas related access whointmediacentrenewsreleasesuhcreport whointmediacentrenewsreleasesnoncommunicablediseases roche access healthcare access healthcare roche dramatic impact hiv response life expectancy age world zimbabwe uganda kenya swaziland many sessions focused innovative ways around value access innovative healthcare south africa empower involve patients example health solutions various stakeholdersa true example botswana technology assessments htas patient centricity patient empowerment subsahara drug development clinical access processes crucial want help patient organisations success idiopathic pulmonary fibrosis respective conversations local level roche supporter european idiopathic pulmonary fibrosis group working based ieepo model focus ensure written declaration calling country regionspecific topics roche organises improved access treatments accepted africa tragically many infants hiv die subsaharan africarequires particular focus experience exchanges patient organisations european parliamenta goal achieved first birthday help diagnose combat hiv continued implement africa strategy local level eastern europe middle special moment everyone affected infections children adults roche partnered involves developing tailored solutions east africa eemea region conducted second devastating disease associated low life unaids clinton health access initiative local partners annual eemea experience exchange patient expectancy lack awareness diagnosis issues presidents emergency plan aids relief organisations latin america first patient treatment delays trust open new chapter global fund global access programme access many countries beset unexpected group workshop health policy april first disease continue support initiated largest infant testing programme challenges take shipping medicines example ever patient organisation exchange subsaharan excellent work patient organisations area world featuring dried blood sampling products shipped special large africa took place abidjan cte divoire patient diagnostic techniqueto date seven million cargo boxes maintain low temperatures group representatives countries took unique diagnosisvital effective therapies infants tested hiv required many cancer medicines opportunity shared best practices strategic diagnosis disease complex vital practical delivering medicines remote planning fundraising communications ensuring right treatment choice roche global access programme one part locations accessible small aircraft work many global local country partners concerted approach support unaids combating specialists roche invented new small cold chain roche also supports training patient organisations including local governments nongovernmental hiv impact unaids programme goes box significantly improved situation part membership european patient organisations ngos patient organisations beyond access already compelling body shipped countries africa academy therapeutic innovation first patient healthcare companies find tailored solutions evidence documenting extraordinary health regions world led project paneuropean innovative medicines barriers diagnosis access also engage economic benefits accrue success initiative firstyear expertlevel online global health institutions world fighting hiv result scaledup hiv treatment goal increase access innovative training course already showed impressive results health organization address key global services overall life expectancy subsaharan africa treatments patients across globe whilst creating prior training trainees advised health challenges sharply increased receiving antiretroviral longterm sustainable business environment regulatory agencies advised htasthese therapy leads remarkable improvements quality figures jumped respectively six months roche able support novo nordisks life people living hiv substantially funding innovative pricing solutions finished course consequently changing diabetes children programme improves economic prospects funding healthcare investment reimbursement individuals became trusted partner discussions example providing free blood glucose monitoring medicines tests critical protect patients tools testing supplies education healthcare supporting healthcare capacity financial burden current economic environment professionals people diabetes well healthcare capacity requires trained teams working increasing demands healthcare systems result scaledup hiv treatment caregivers seven countries africa together right equipment provide best making challenging payers fund latest children reached date chance successful treatment fundamentally treatment options many patients services overall life expectancy sub clinics established healthcare believe everyone deserves access medicines using flexible pricing approaches including professionals trained region currently least access differential pricing support patient access saharan africa sharply increased united nations population division world population prospect rosen et al effect antiretroviral therapy patients economic wellbeing fiveyear followup aids lifson grund b increased quality life immediate art initiation results start trial conference retroviruses opportunistic infections roche access healthcare access healthcare roche collaboration private insurance companies provides increased access cancer care supported development new private insurance policies covering pipeline additional cancer therapy cancer insurance policies cancer insurance millions global regional medicines scientific clinical insights leading coverage since many cancer us develop effective medicines insurance products global pipeline countries involved partners involved used across multiple indications combination estimating number continue grow drugs benefits patients vary believe different benefits furthermore currently exploring options reflected way medicines priced marking expand initiative beyond cancer funding shift traditional approach pricing started explore expanding scope areas many cancer insurance products development multiple providers number people gaining access cancer care expected grow strongly medicine pack vial implementing molecular diagnostic tests multiple sclerosis personalised reimbursement models prm diabetes currently running prm pilots across europe currently working global regional countries demonstrate flexibility partners countries including direct insurers generation collaborate us centers august agreement signed kenya systems approach work ensure reinsurers one benefit collaborating right disease control prevention training ministry health roche heralded start required infrastructure place expect partners able replicate successful next generation lab technicians benefitting activities include breast cancer awareness prm implemented next couple years insurance products regions many new healthcare project management knowhow within programmes improvements screening countrybycountry basis countries insurance products pipeline tremendous diagnostics division act catalyst diagnostics training five new oncologists already reporting first successes potential expand coverage many millions bring hospital builders medical devices companies six oncology nurses support development people due proven success approach region bestpractice national treatment guidelines private insurance complement public model replicated companies increase number cancer treatment centres healthcare systems organisations healthcare systems formal agreements memorandums kenya access medicine made available work private insurance companies make understanding signed several subsaharan patients treated public institutions meaningful impact patient access diagnostics focus partnerships progress africa countries including ghana kenya following government kenya roche jointly covering treatments creating private funding part africa strategy roche improving first agreement cte divoire aim costs solutions countries public coverage step patients journey addressing four agreements improve access timely inadequate working together local insurance key access factors awareness diagnosis healthcare precise diagnostic services treatments make partnered breast cancer initiative company partners focusing cancer coverage capacity funding aim bring quality highquality care widely available hold summit march offering breast cancer enabled launch several private insurance healthcare africans regardless education multidisciplinary teams healthcare products countries like china india portugal live ability pay work towards goal ghana agreement ministry health professionals subsaharan africa event vietnam thailand late thoughtful multidisciplinary approach signed improve access care people ghana welcomed attendeesincluding surgeons types cancer insurance policies available partnerships collaboration investment breast cancer viral hepatitis signed may radiologists pharmacists nurses oncologists different countries millions people empowering local healthcare providers initiative includes setting disease awareness academic public hospitals six different programmes conducting screening promote early countries teams worked together identify gaps many fundamental barriers regions detection establishing two centres excellence respective institutions prioritise needs contributed subsaharan africa lack basic infrastructure improving diagnostic facilities treatment centres develop month action plans improve eg access hospitals clean water limited training specialists developing national cancer patient care strengthen centres excellence types cancer insurance policies availability treatments adequate care registry better understand disease burden clear roches remit build hospitals working establishing national treatment guidelines different countries provide coverage hire physicians roche contributes supporting training healthcare professionals supporting millions people pragmatic epidemiology sociodemographic data fredhutchorgenlabsphsprojectsbreastcancerinitiativehtml roche access healthcare access healthcare roche marianne gilchrist swiss joining forces address oncology needs china grew insurance industry years data lifeblood insurance industry father worked scottish life assurance roche found partner provided us company age first afterschool job accurate information incidence cancer filing life insurance policies safe scottish disease progression treatment pathways life 's head office edinburgh scotland associated costs allowed us work local international insurance companies design finishing degree oxford worked policies cover oncology treatment able several years financial services marketing calculate risks insurance companies run advertising discovered affinity asia sustainable business still offer individuals realised world insurance affordable premiums truly felt sense purpose take break path study clinical reinsurance company swiss takes part psychology set private practice singapore risks well rewards important note learned years served insurance policies china stipulate well sure continue use companys productsthis expanding overall access treatment joined swiss head health solutions asia private insurance still developing many addition data roche provides education countries asia healthcare costs often programmes cancer prevention leverages paid pocket illness cancer connections leading physicians give wipe lifetime savings insurance agents basic understanding oncology swiss works government regulators help closing societys protection gaps ensure patients understand policies china cancer leading cause death buy coverage need numbers shocking almost three million fatalities four million newly diagnosed cases every opportunities opening private insurance year oncology treatments covered china collaboration roche illustrates governmentprovided healthcare swiss saw creative approaches close societys protection opportunity address treatment gap gaps demonstrates power crossindustry unable alone partnered partnership improving access healthcare roche chen w zheng r zhang et al cancer statistics china ca j clin roche people people roche people material topics covered chapter employee engagement talent retention compensationbenefits leadership commitments employees making valuable difference patients organisational effectivenesss committed best work contribution un sdgs integrity courage passion diversity inclusion vital foster innovation encouraging different perspectives ideas thinking styles strive create work environment includes facets diversity roche people people roche w orking roche means job opportunity make difference think act boldly part global community talented people engagement roche successful careers great work environment employees make roche distinct special people feel valued respected south san francisco employees volunteered total hours donated usd genentech gives back week highly engaged people deeply connected purpose patients take time ask every employee opinion need next able achieve highest standards measure engagement regular global employee surveys act results together diversity inclusion foster innovation results reflect progress roche provides people rewarding enriching building even better place work fundamentally believe innovation comes top key positions diagnostics filled women experience means focusing things leveraging diverse perspectives talented end figure risen matter respect diverse perspectives recognition giving back local communities people strive create work environment since expanded programme include celebrates successes well healthy risktaking present countries around includes facets diversity age gender race experience developing regions also leaders embrace values leadership world proud part local communities ethnicity sexual orientation religious affiliation provides element reverse mentoring allowing commitments development enables meaningful headquarters basel also less visible differences educational sponsors gain deeper insights around sites engage variety ways support background professional knowledge personality challenges well opportunities new giving back local communities type thinking style life experience emerging markets consistently voted great place work employees south san francisco example one leadership commitments take increasing employees experience participate different forms organised volunteer genuine interest people emphasises established developing regions employees external institutions consistently rank us activity cleaning school working importance persons uniqueness also global presence critical employer choice roche genentech local food bank weeklong period called importance person feeling part team understand specific challenges circumstances recognised forbes among americas top companies genentech gives back total projects engaging inclusiveminded leaders markets operate want work ranked first second biotechnology list completed volunteers special launched inclusion index pharmaceuticals increase number employeesparticularly renowned organisations great place work institute give back week involving nonprofit organisations division asking employees well leaderswho experience established top employers institute placed roche best places total hours volunteered building respect gaining trust developing regions among things support work lists number years several countries including usd donated employees hallmarks inclusive organisation international assignments help individuals gain brazil china denmark france germany italy mexico poland index measure inclusion rochewide part experience one four assignments spain switzerland uk read community engagement chapter next global employee opinion survey geos developing regions also look experience hiring hires key diagnostics division pioneered programme leadership positions developing regions experience providing opportunities highpotential women bringing diverse experience capabilities systematically acquire sponsorship would establish company ensures leadership readiness another pathway valuable feedback continued growth markets career progression approach effective roche people people roche people fiveyear goals based figures developing leaders representation women fostering strong leadership key leadership roles representation people established want people great leaders executive leadership programme developing region experience key leadership roles instil values act role models well assessing major trends changing healthcare foster accountability leadership commitments environment growth digital healthcare throughout levels company order focusing new leadership capabilities top quartile continuously cultivate leadership culture offer require leadingroche broad portfolio tailormade leadership development participants reported positive leadership change ranking overall employee engagement score options enhance leadership competencies skills within six months participants measured global employee opinion survey managers said noticed positive leadership addition local courses leaders change employees six months well attended global leadership development programmes genentech launched initiative called leadership goal baseline include initiatives leading excellence enabling leader evaluate leadersroche leading peopleroche live promise leadership commitments company values want increase number programmes push boundaries outside already seeing longerterm leadership leadership commitments classroom well example njia impact njia one year first group travelled leaders experience means path kaswahili programmelaunched tanzania roche participants agreed take genuine interest people involves roche leaders travelling profound impact leadership behaviour established developing regions listen carefully tell truth explain tanzania working partnership local mindset meanwhile tanzania campaign resulting empower trust people make decisions nongovernmental organisations ngos address programme increase awareness cervical discover develop potential people current healthcare challenges country cancer screening already led new funding strive excellence extraordinary results leaders gain ontheground insights needed operate allocation nursing staff training set priorities simplify work emerging markets work ngo congratulate people job well done partners implement sustainable solutions locally roche people people roche employees worldwide europe north america asia attracting retaining best talent providing space innovation cultural diversity growing emergence also offer numerous additional benefits andor multigenerational workforcewhich means five amenities employees vary site site latin america africa australianew zealand generations people working often together may include pension schemes health insurance officeis increasing millions women childcare medical facilities flu vaccinations preventive enter global workforce coming years health screenings discounts local retailers great place work attracts best people transportation tofrom workplace aligned values purpose paramount continued success accommodate individual circumstances employees operating unit employees per function support flexible working models actively rewarding recognising employees use many countries enable employees work roche pharmaceuticals roche diagnostics marketing distribution research development services efforts strike attractive balance home buy sell days job share highly competitive base salary performancelinked seen particularly sharp increase utilisation rewards flexible benefits tailored different flexible working models allowing working parents chugai corporate manufacturing logistics general administration needs key focus roche connect others balance personal time work time programme promote ownership partnership optimal way latin america circumstances roche allowing employees purchase roche demanded even greater accommodation roche stock discounted price many countries created regional flexible benefits programme incorporated china initiative allow additional alternative compensationsuch seen highest participation rate since launch fuel vouchers areas fuel shortages hire promote diverse group talented people furthermore proactively encourage help new ideas innovative solutions scientists publish work want third year applause flourish great research opportunity build programme online tool employees use external reputation engage promoting employee wellbeing recognise directly ecards remains one goals hire retain great scientific minds reward point nominations overall usage best scientists world live well find balancean initiative foster since launch peertopeer expanding recruitment efforts beyond ultimately committed cultivating rich culture health wellbeing among roche employeeswe recognitions among employees traditional universities actively collaborating working environment one allows individuals promote awareness education healthy life styles academic institutions attract best talent thrive make difference patients nutrition emotional wellbeing offer resources giving people space innovate also offer number internships post gyms sports clubs medical services counselling yearly recent years challenged thinking doctoral research positions global wellbeing week part initiative involved find best people identify participation sites nurture potential assess performance read harukus story targeted initiatives leaders better equipped number employees expressed fulltime equivalents roche people people roche haruku shirahata university tokyo exciting make real contribution started december raised work able identify potential efficiency hand laboratory work university gains reducing waste tokyo professor hirokazu sugiyama department chemical system engineering supervisors approachable open asking candidates new internship programme discussing projects answering questions roche switzerland lunch coffee breaks many opportunities network discuss ideas meet new people little nervous leaving home academia first time found courage go ahead internship clear diversity began twomonth internship august important roche colleagues happy first time living outside japan away someone japan team valued family lot new shared input also pleased see almost half apartment basel interns commuted employees kaiseraugst women every day kaiseraugst roche produces drugs treat cancer hepatitis many diseases back university tokyo pursuing masters degree doctorate chemical engineering everyone plays valuable role experience roche brought closer first day plant manager welcomed new impact work patients convinced interns employees emphasised every chosen right career path single one us would play important role producing lifesaving medicines patients right handson experience also showed beginning aware teamwork engineering add value team pharmacists important chemists specialists comes making processes efficient environmentally facility liquid sterile drugs main friendly exciting make real contribution project optimising batch production rubber materials used stoppers glass vials syringes would definitely recommend programme rubber materials critical maintaining students key getting sterility pharmaceutical products felt experience make extra effort ask questions could truly make difference making products safe share thoughts engage people patients well contribute sustainable remember even though contribution may one batch production proud see many make difference lives patients roche safety health environment safety health environment roche safety health e nv ironme nt material topics covered chapter strive ensure safe working environment occupational accidents protect health employees emphasis environmental responsibility sustainability allows us expand business contribution un sdgs minimising ecological footprint remediation kesslergrube former landfill site grenzach germany modern safe remediation methods protect water nearby rhine river serves source drinking water approximately million people downstream roche safety health environment safety health environment roche w e made significant progress increasing use renewable resources procedures safety security health sites frequency proportionate environmental protection embedded throughout risks conduct training programmes solar power plant genentechs oceanside us facility expected provide sites total electrical power requirements operations important components roche employees total employees sustainability concept high standards participated hours dedicated training area built solid foundation prevention average approximately hours per employee continually improve site infrastructure enhance focus security employee health safety efficiency reduce environmental impact ensuring occupational health safety protecting employees physical assets critical expanding successful business committed essential categories work roche information integrity brands improving track record monitor results safe whether tasks urgent complex routine products principal concerns roche preventive progress ensure compliance standards aim minimise number working days lost measures priority aspects security objectives aim cover least due occupational accidents per employee per year key performance indicator roche accident rate rar number one focus introduction new accidents causing absence work lost time roche security incident reporting tool improving monitoring performance accident rate ltar per worked hours global platform reporting incidents issues company complex production operations track achieve safety goals keep occurred application allows affiliates affiliates around world roche exposed rar ltar despite group security gain thorough overview global risks ranging dependency limited preventive measures employee drowned adverse events losses occured safety health fossil fuels source energy access clean taking part water sport activity year focus measures training based environment water worstcase scenario fatalities company event profoundly regret tragic lessons learned rochecom mitigation plans help reduce risks also accident offer sincere condolences environment invest innovative technologies perform audits victims family friends second security focus eastern europe security workshop held budapest hungary illness rate accident rate rar site security officers eastern european sites losttime accident rate number workrelated accidents discussed challenges good practice three key working days lost per year due accidents fiveyear goals topics region prevention response counterfeiting products information security minimising ecological footprint risks intellectual property measures aware much business dependent protect well training adequate security increasingly scarce natural resources part measures small affiliates commitment towards sustainable development duty responsibility use new sustainable technologies processes thereby ecobalance energy consumption water consumption general waste minimising impact environment roche safety health environment safety health environment roche emissions water primary energy emissions air mainly co roche ecobalance landfilled waste reduced air pollution also raised averagesized homes within community water consumption awareness environmental protection course year lease oceanside noise encouraged sustainability solar facility save usd year energy costs also decrease energy energy consumption terajoules used buildings stationary equipment gas fuel oil waste electricity district heating across roche group total scope less roche depends upon nonrenewable resources joint district heating cooling c renewable scope share sustainable energy less vulnerable company supply constraints heat c groundwater instead steam energy volatile market prices set energy chillers scope saving action plans across sites innovative replacement compressed air systems consumption technologies upgraded infrastructure energy recovery technology gjemployee example large solar panel array started operations scope facility oceanside covering terms energy represents reduction heat business flights sites electrical power similarly installed consumption gj steam gj data collected group gj gigajoule additional solar panel arrays site kaiseraugst c renewable heat reduction goal located close basel compressed air reduction co emissions tonnes replacing fossil fuels renewable energy nonsustainable sustainable reducing carbon footprint purchasing large proportion energy used operations energyefficient equipment including hybrid cars measure impact environment using currently comes fossil fuel sources oil natural capital increasing sustainable energy supplies well ecobalance metric developed swiss federal gas working maximising efficient energy completed pilot test new natural monitoring employee travel needs work processes office environment want usage increasing use sustainable energy whilst capital protocol internationally agreed framework since projects completed improve ecobalance compared continuing expand global business longer sets businesses measure monetary resulting avoidance tonnes co improvements decreasing energy consumption term goal reduce energy consumption per value environmental impacts dependencies emissions leading estimated cost air emissions volume consumed water employee approximately compared society natural capital saving chf million per year well reducing weight general baseline levels energy consumption assessment nca undertaken included high level chemical waste led improvement decreased sales grew assessment roches overall value chain proved roches basel site developed energy vision achieved results despite useful highlighting complex broad spread initiative supports corporate goals continued growth business midterm goal reduce consumed energy natural capital dependencies impacts reducing energy consumption increasing scope scope sources per employee study also involved detailed assessment use renewable energy innovative technical internal ideas trigger significant improvements within facilities also plan roches operational sites switzerland outcome solutions meant huge monetary savings encourage welcome suggestions increase proportion sustainable energy demonstrated natural capital perspective roche equally beneficial environment employees improving sustainability culture compared levels genentech swiss sites well managed good example energy vision action performance held seventh facility oceanside helped make substantial significant societal impacts greenhouse gas renovation staff restaurant edition ecompetition resulting ideas progress toward goal completing emissions roche already carefully managing basel headquarters led savings submitted winners past ecompetition solar panel array project consists material issue also assessed results approximately chf via submissions helped us improve many different panels provides sites total protocol study compared existing eco insulation optimisation building areas including energy conservation waste reduction electrical power requirements capacity balance methodology societal impactmonetary decreased consumption water raw materials megawatts solar plant could power almost valuationresults found highly comparable roche safety health environment safety health environment roche co equivalent emissions metric tonnes landmark deal nearly countries agreed either working implementing programmes phase hydrofluorocarbons powerful increase efficiency water usage genentech ghgs seen significant step curbing south san francisco us site employing innovative scope global warming approaches reduce water withdrawal improve fuel combustion wastewater management since site halogenated hydrocarbons recognition programme reduce emissions reusing approximately reverse osmosis reject scope ghgs mitigate climate change water cooling towers cooling towers use pre identified global leader actions equivalent approximately water per marketbased strategies awarded position global year approximately per year comes locationbased climate list developed cdp former carbon reject water since implementation total scope marketbased disclosure project environmental initiative led incremental scope savings amounting usd business flights halogenated hydrocarbons tonnes energyintensive utilities water usage discharge waste inventory due changes reporting methodology number different reported compressed air liquid nitrogen consumed water withdrawn million cubic metres global inventory including chugai genentech ventana water consumed ecobalance scores thus effectively validating improving energy efficiency also relevanta million cubic metres approaches study concluded ncas reduction ghgs per employee tenyear environmentally sustainable products wastewater discharged could provide roche valuable insights enhance period absolute scope consider entire lifecycle products treatment plant decisionmaking better manage risks scope ghg emissions cut terms environmental impact aims million cubic metres opportunities many contexts includes reduction achieved implementing energysaving safeguard ecosystem protect business organic matter example relation water management water measures reducing amount fuel use longterm financial reputational risks discharged waterways scarce regions heat cool operate sites key contributor mabtherarituxan avastin herceptin perjeta treatment tonnes success site oceanside switched lucentis monoclonal antibodies together heavy metals discharged increased energy efficiency reduce co solar power generated chf billion sales waterways business continues grow committed low excretion rate judged treatment kilogrammes maintaining low level emissions air halogens halogenated refrigerants fire respective authorities present significant achieved far making improvements suppressants ghgs remain risk sewage works surface waters feasibility studies also ongoing method manufacturing sites emissions air atmosphere long period time therefore termed benign nature constitute treating manufacturing processing equipment nitrogen oxides sulphur dioxide particulates therefore committed reduction use environmentally sustainable compounds whereby surfaces become superhydrophobic decreased respectively halogens next five years creates selfcleaning effect protein emissions volatile organic compounds increased addtion reduction achieved managing limited water resources emissions air sites low legacy roche sites continue examine available water usage remained relatively unchanged recognised leader corporate levels means new processes activities alternatives work refrigeration fire several years procedures ensure efficient well timing sampling result large suppression suppliers achieve reductions water use whilst allowing business continuity action climate change result temporary fluctuations majority importance approach paralleled goal reduce water consumption per employee greenhouse gas ghg emissions originate agreement taken united nations environment weighted according water stress commitment protect natural resources transformation use energy goal programme meeting kigali rwanda october respective region end roche sites roche safety health environment safety health environment roche sustainability protection people cellular debris remain solution adhere activities kesslergrube grenzach germany determined create longterm social metal surfaces modification targets well environmentrelated activities genentech value community continued environment top priorities reduction water used cleaning site south san francisco oneoff activities remediation programme previously used per day simultaneously reducing usd two million contributed tonnes generated landfill sites former site nutley us roche spent cleaning year furthermore self terms regular production reducing agreement reached hackensack university cleaning surface would reduce need phosphates already low volumes chemical waste health network seton hall university create used cleaning process thereby decreasing general waste incinerated landfilled medical school part former site roche environmental impact discharge nearby decreased retain responsibility environmental cleanup completed excavation bodies water also support global efforts beyond divestment started end year thanks careful kesslergrube water protection aim reduce total wastewater activities optimising packaging within supply planning roche ensuring safe efficient kesslergrubede toxicity selected production plants chain way sides atlantic setting infrastructure necessary execution complex programme reduce perimeter versus level approximately half water roches kaiseraugst site optimised remediation former kesslergrube landfill site emissions minimum draw used cooling circuits although procedures delivering small quantities material water chemically contaminated analyse c temperature changing shipping boxes directly discharging furthermore allow efficient agile shipping well discharge wastewater pollutants able cope smaller quantities small comply fully relevant regulations including change aids business continuity mitigating risk pretreatment requirements transportation capacity restrictions addition left dr richard hrzeler roche boris krause friends earth germany dr tobias benz mayor grenzachwyhlen samer hijazi bauer umwelt gmbh initiative reduces freight costs uses less packaging discussing progress remediation activities kesslergrube germany minimising waste maximising recycling material reduces material waste co emissions aim implement following waste management small change resulted approximate strategy activities avoid reduce reuse savings chf genentech south san recycle thermally destroy permit landfilling francisco proposed process making last resort even inert packaging supply chain far less complex cutting materials slag ashes depending consolidating number shipping boxes availability suitable local wastetreatment plants saving usd million well cutting co may sometimes dispose nonhazardous general emissions due reduced shipments waste authorised landfills objective avoid disposal chemical waste hazardous materials waste tonnes landfill sites accept responsibility waste generated operations including waste previously deposited sites landfills using general waste baseline aim reduce general waste per employee generated landfilling organic chemicals chemical waste chemical waste incinerated land filled generated increased largely due remediation construction waste substances chemically reactive roche safety health environment safety health environment roche ali afghan genentech joining company helped save life left iran follow three brothers recovering leukaemia wanted give already emigrated us courageous mother something back disease tragic events raised four boys single parent insisted family preceding years transformed began get higher educationbut limited ask really mattered academic opportunities iran time earned bachelors degrees general science new chapter mechanical engineering portland state retiring intel decided use university pursued career engineering including skills experience help others came years intel got married opportunity join company helped two beautiful daughters save life lifechanging news became progamme director genentech went routine medical checkup huge project upgrade facilities south san doctor detected elevated white blood cell count francisco environmentallyfriendly cooling referred specialist gave shattering systems making contribution better diagnosis chronic lymphocytic leukaemia cll planet daughters children stage like hitting wall miles hour world stopped parallel asked speak groups employees experience leukaemia patient wasnt remember vividly doctor showed bell easy first open private life curve average survival rate four eight years many people however spoken many older men cll late groups time hear peoples comments wasnt much reliable data survival chances experience cancer patient touches inspires say makes difference pull together couldnt let family daily work next generation lifesaving friends started chemotherapy medicines came unexpectedly combined rituxanmabthera roche monoclonal become clear story patient antibody targets specific lymphocytes six another way giving back people video months treatment doctors gave exhilarating helped much rochecomarpat news body free cancer new lease life roche community engagement community engagement roche community e ngage nt material topic covered chapter collaboration international local partners community engagement support programmes result lasting improvements sustainable benefits communities contribution un sdgs operate society general schoolchildren performing chemical biological experiments experio roche school laboratory kaiseraugst switzerland roche community engagement community engagement roche f century philanthropic engagement focused building stronger healthier communities operate believe role good corporate citizen support social causes science education providing longterm disaster relief programmes well arts cultural projects communities experienced major roche started partnership maharishi institute johannesburg south africa cover universityeducation costs students aim make lasting impact peoples lives natural disaster especially developing world support projects result lasting sustainable focus addressing needs communities benefits initial emergency phase partner roche operates many philanthropic local authorities relief organisations help philippines completed support developing world well developed activities selected managed locally roche affected communities rebuild prepare project open arms foundation countries cases respect independence affiliates around world work partners future contributions range product provided costeffective solar light sources people autonomy partners areas research share commitment longterm solutions donations logistical support transfer rural slum areas continue affected education objective strengthening communities knowledge expertise aftermath typhoon haiyan sustainably expect partners share risk developing areas fund education programmes commitment investment resources one example humanitarian engagement haiti devastating earthquake support talented students disadvantaged implementation project nepal experienced earthquakes supported construction two disasterresistant backgrounds started partnership affected eight million people destroyed schools partnership swiss agency maharishi institute south africa cover corporate level supplement local activities homes local management centre development cooperation schools universityeducation costs students additionally needed support areas roche may responded donating vials antibiotics opened sustained hurricane matthew roche south africa supports health education yet operate manage longterm international phased approach since partnered october unaffected wellness programme students career development programmes world wildlife fund nepalese government personal finance workshops employed transnetphelophepa healthcare train mobile local organisations support rebuilding pakistan partnered citizens graduates learnership programme clinic bringing medical care medicines communities ecosystems langtang national foundation last six years establish people per year remote areas south park also working twoyear build nepal extend primary school rural jacobabad nepal partner habitat africa since project habitat humanity international built following extensive flooding area roche childrens walk worldwide fundraising together supporting rebuilding humanity international world employee project initiated support salme municipality nuwakot district investing education childrens initiatives malawi saw houses destroyed earthquakes believe longterm impact education wildlife fund local authorities communities around world project help cover urgent needs improving lives children roche continents partnership salzburg families provide access safer disaster families communities belong help rebuild communities ecosystems festival launched encourages resistant housing solutions partnership local institutions support universitylevel students explore common education programmes designed inspire children two earthquakes ground innovation arts science youth primary grades university roche community engagement community engagement roche since opening experio latin america support fundacin educacin leading local academic organisations including fostering interest research peru colombia el salvador guatemala hong kong education city well hong experio roche school laboratory opened roche school laboratory received goal develop middle class roche provides four kong university science technology school february kaiseraugst switzerland year scholarships students studying engineering science joint roche pharmaceuticals auspices human resources apprenticeship visitors economics leading collegesuniversities india roche diagnostics initiative science competition department stateoftheart laboratory support collegeuniversity scholarships nine mentorship programme aims encourage designed enable pupils region students kiran childrens village home secondary school students use science acumen primary school college experience practical school childrensome disabilities innovative thinking solve daily health issues application science technology engineering falls water using corrective pen come poor families rysa also aims shine spotlight importance mathematics stem subjects workshops always start playful way also experio roche innovation science education uncover high standard equipment professional give deep insights drug synthesis polymerase experiorochech researchbased healthcare company science young science talent hong kong since supervision makes experio roche unique chain reaction pcr gel electrophoresis technology core inception students switzerland allows schoolchildren try host show basic techniques applied research supporting many years supported multiple schools participated different experiments supervision labs production lines throughout company communities programmes promote interest disciplines specialists activities include programming robots since opening experio roche received rochecom among young people building foundation futurelab genentech science education soldering electronic circuits understanding visitors expects reach mark philanthropy science technology providing realworld science programme developed partnership chemical process involved drop ink visitors year skills enabling continued education careers south san francisco unified school district biotech hope help grow next generation support science education every grade level innovators elementary school high schoolimpacting student participating helix cup annual science competitionan integral part genentechs futurelab programme students south san francisco futurelab roche young scientist award hong kong supports teachers professional development futurelab us experio roche switzerland students field trips access scholarships leading examples efforts support classrooms equipment supplies young scientists across globe teachers need curriculum also gives employees chance get involved biannual roche young scientist award rysa volunteering mentoring alone launched partnership genentech employees volunteered hours programmes offer exciting science experiences local students students south san futurelab also includes creation science garage stateof theart biotech facility local francisco schools benefiting highschool students take handson biotech classes broke ground september genentechs futurelab science education project highschool students participate biotech curriculum programme building completed roche community engagement community engagement roche sara shayesteh south san francisco unified school district futurelab means world teacher always loved math science handson science eye opener educational career path seemed clear graduated futurelab driven enthusiasm energy san francisco state university degree genentech employees care biology chemistry business worked local community volunteer afterschool tutors research lab local biotech company work math science serve chaperones science interesting felt something missing field trips assist classroom handson competitions inspire students apply scientific financed college studies partly tutoring principles real world high school students math science enjoyed connecting seeing flash thanks support genentech futurelab excitement eyes understood difficult also includes two full college scholarships concepts started parttime tutoring construction highschool biotechnology centre decidedafter soulsearchingto pursue called science garage open excited masters degree education stanford university part project opportunity roll new biotech curriculum science garage started working science teacher el camino high school south san francisco making difference one student time unified school district students one students story great example futurelabs families living poverty impact family recent immigrants elementary students englishlanguage learners us bright extremely interested sciencehe wasnt excelling science classes young people natural scientists attended several handson science field trips curious world around way genentech opportunity see science taught classrooms today n't science come life everyday work always successfully reach engage students learning transformative events last bumped english first time knew could done shared hes determined attend genentech invited join brainstorming college study computer science fact session focused improving science education enrolled biotech class south san francisco really hopeful possibilities discussion emerged feel lucky part futurelab witness futurelab programme positive impact students means world teacher roche integrity business integrity business roche integ r ity material topics covered chapter drug efficacy safety counterfeiting data transparency clinical trials bu sine compliance disease awareness treatment education patient organisation support supply chain management biosimilar safety roche believe right thing means good business thats set high standards ethical contribution un sdgs behaviour live every day critical part supply chain portugal pharmaceutical warehousing partner rangel roche integrity business integrity business roche w e know integrity foundation business license operate key ability make lasting impact public health compliance starts leading example global compliance efforts supported senior executives act role models continually dedicated organisation led chief compliance invite suppliers work jointly us improving supply chain sustainability reinforce importance compliance levels officer affiliates networks compliance company involving middle management vital functions assisted global functions local line strong compliance culture management ensure necessary compliance developed middle managements capabilities infrastructure place training standards transformed supplier also call employees suggest improvements compliance leaders ensure high ethical met high level awareness sustainability audits assurance visits creating innovations internal processes services supplier code standards firmly embedded daily working life compliance mutual benefit improving relationships created platforms employees submit conduct believe every employee roche suppliers service providers made ideas eventually lead savings rochecom responsibility act integrity take goal create atmosphere mutual trust supplier sustainability assurance visits worldwide company platforms exist mannheim suppliercodeof systematic sustained approach anchor issues discussed openly employees direct spend area goods used directly penzberg germany well rotkreuz basel conduct compliance culture compliance concern encouraged speak production service providers switzerland across sites annual net savings using different channels tolerate sixto sevendigit range around psci fostering global compliance culture retaliation employee raises collaborate supplier audits ideas implemented rotkreuz one pscinitiativeorg code conduct guides roche employees concern good faith allegations investigated pharmaceutical companies umbrella idea led optimised release procedure reagents acting integrity times employees complete substantiated corrective measures pharmaceutical supply chain initiative psci using annual savings chf mannheim mandatory training ensure understand code sanctions carried unified joint audit protocol focusing latin production coagulation test streamlined including voice compliance concerns america engaged suppliers reduce led annual savings eur business practices behaviour eg conflict interest make sure suppliers service providers environmental footprint average bribery improper advantages discrimination subject standards employees also conducted joint risk assessments sole source harassment code expresses supplier code conduct included contracts suppliers mitigated identified risks thereby expectations roche towards employees offer elearning programme help making supply resilient us service compliance terms patient safety product quality open suppliers service providers understand provider relocated office closer facilities roche group code constructive dialogue stakeholders expectations industry standards hence provide us better service employees used roche group speakup line conduct code conduct applicable even stricter available languages countries chief rochecomcode local standards strongly believe compliance officer received reports relating alleged ofconduct consistent roche approach across globe violations code conduct via business ethics incident reporting system unfounded still investigation substantiated result employment contracts agreements business partners terminated grounds unethical behaviour roche integrity business integrity business roche patient safety comes first arising country serialisation allows component patient management ivds regulatory authority distributor pharmacy rigorously validated analytically clinically continuously improving high standards physician trace verify time us laboratorydeveloped tests ldts inhouse product handled within roche tests far subject regulatory supply chain serial number genuine oversight commercialised devices tests continue work health authorities around light concerns around safety efficacy voiced patients general public many stakeholders harmonisation ich guidelines quality world share approaches insights us use ldts routine clinical place invaluable trust company management system inspected relevant health guaranteeing safety traceability interests decisionmaking roche become actively engaged right expect roche medicines diagnostic authorities worldwide well internal quality patients stakeholders example public debate assessment products safe reliable highest quality compliance audits regular basis ensuring invited hosted numerous meetings delegations ldts new regulatory framework available compliance good manufacturing practice health authorities educated trained inspections conducted regulatory product security meetings sharing best practice animal testing meet expectations enforcing authorities worldwide demonstrated commitment towards patient safety clinical trials new medications standards operational performance include serialisation traceability techniques conducted humans regulatory bodies worldwide constant review ongoing improvement pharmaceutical production facility shanghai beneficial wider health community require efficacy safety data based animal quality standards precision clarity china illustrates dedication quality testing regulations allow packaging product information site successfully passed regulatory aligning biosimilar guidelines global standards scientifically possible ethical roche employs monitoring link international supply audits health authorities around world world health organisation medical testing procedures require chain addition continue strengthen shanghai site helps meet growing published guidelines defining evidence required animals switzerland support r research business continuity management ensure pharmaceutical needs china also production one biotherapeutic product considered foundation provides funds research sites affiliates strategies tactics place hub many parts world biosimilar another recommendations outlined projects promoting rs replace animal tests deliver minimum level vital products services guidelines built national possible reduce number animals enhancing safety quality serialisation biosimilar regulatory processes many studies refine existing practices roche actively ensuring patient safety means collaborate patients must complete confidence roche countries around world order ensure engaged discussion future continuously regulatory agencies carefully check medicines authentic highquality products patient safety roche believes local regulatory foundation lead federal food safety reports adverse events experienced patients although problem counterfeit adulterated pathways relating biosimilars align veterinary office consideration given communicate transparently regularly drugs existed decades risks increased global standards set roche respects establishing national r competence centre product quality roches safety risk management dramatically recent years internet sales legitimate undertakings competitors including department systematically monitors roche drugs difficulttocontrol sources generic biosimilar manufacturers expects play leading role sharing best practices worldwidebefore launched adverse comply applicable laws regulations animal testing china example key opinion events recorded global database reviewed roche implemented initiatives improve upon industry codes protects products leaders representatives contract research reported promptly appropriate regulatory existing regulatory requirements help create interests unfair competition organisations invited roche authorities require employees report drug new standards product safety security quality innovation center shanghai discuss stateof safety quality issue immediately complete one way enhanced safety quality rigorously validating diagnostic tests theart practices participants signed china animal animal studies annual awareness training adverse event reporting medicines serialisation understand worlds leader vitro diagnostics ivd welfare nonclinical quality charter goes rochecomanimal labelling every single package unique serial roche develops diagnostic tests critical beyond current local regulatory requirements welfare medicines must meet highest quality standards number standard started times roches pharmaceutical quality systems roll safety feature numerous countries processes comply international conference supportive new serialisation regulation roche integrity business integrity business roche matter engagement engage government officials industry benefit datasharing come life bodies contribute public debate working clinical development plan antibiotic earning stakeholders trust development effective public health laws needed specific data advance development regulations policies data transparency policy adopted european medicines agency roche received data enhancing access healthcare within six weeks rather years would european patients forum epf highly taken without data transparency essential earn trust stakeholders contributions patient organisations regarded voice urged politicians reinforce euwide build understanding concerns truly total amount chf million collaboration access new medicines roche strive make clinical study information embedding daily business able making significant contribution new access available patients physicians researchers jointly develop solutions annual sustainability reimbursement models eu support subject protection patient privacy forum brings together internal stakeholders financial contributions patient organisations shift traditional approach pricing medicine commercial confidentiality collaborate external experts discuss innovations nonfinancial contributions patient organisations pack vial multipleindication pricing range organisations wellcome trust enhancements commitments engagements service contracts patient organisations outcomebased approaches also advocate transcelerate involved advancing developed key performance indicators kpis development data infrastructure implement opportunities datasharing measuring monitoring progress many areas dedicated engaging transparent dialogue approach relevant stakeholders healthcare professionals nature introduced updated version roche collaboration includes support attend important us centers medicare medicaid policy sharing clinical information document foster transparency relationships congresses conferences fields comply services cms federal agency charged reflects changes regulatory environment patient organisations healthcare professionals disclosure requirements example us implementing innovative payment delivery encourages greater understanding approach patient organisations key partners us sunshine act efpia disclosure code models across healthcare system decrease cost belief value datasharing provides provide forum patients caregivers share adapting disclosure guidelines improved enhance quality care cms currently overview guiding principles well stories experiences also help shape internal external transparency testing models including accountable care details regarding information available current future healthcare environment organisations bundled payments oncology care channels use making collective voices heard help us contributions healthcare organisations model medicare part b drug payment model understand human experience personal total amount chf million models aim transition traditional engaging political institutions challenges disease providing us invaluable feeforservice valuebased payments roche remain independent political affiliation nonfinancial insights improve product development genentech active discussions us however support number associations reporting clinical trial programmes research commercial public payers role political institutions switzerland spent rochecomnon education healthcare professionals certain innovative payment models play chf million includes payments financialreporting support patient organisation always based education patientsgeneral public healthcare reform industry associations various chambers written agreement states purpose support healthcare infrastructure commerce financial assistance trade unions working amount financial support significant support personalised healthcare sharing data advance scientific progress donations political parties cantonal patient groups indirect nonfinancial benefits accordance patient screening share clinical information understand federal level donations political parties rochecom industry guidelines make details helps physicians patients healthcare providers lowdoubledigit thousand range swiss francs patientorganisations relationships patient organisations public make informed treatment decisions enable together accounted less total researchers advance scientific progress saw contributions donations roche integrity business integrity business roche eduardo rangel rangel logistics solutions special task based shared commitment learned value hard work early life shook hands started intensive period age already trainee customs office collaboration rangel invested heavily new porto studying administration accounting warehousing cold chambers transportation night within three years named head boxes remain constant degrees celsius export department roche quality experts came site lisbon train people knew teamwork based aged took bold decision start shared commitment get lifesaving products freightforwarding company together two hospitals pharmacies patients need colleagues tough find investors customers convinced people willingness put january went live soon afterwards long hours determination succeed introduced track trace website engineers created programme roche could follow shipments even monitor process customs declarations electronicallywe realtime temperatures delivery trucks first company portugal offer software something never done biggest challenge came looking back proud say kept creation european union phasing promise miss customs duties within europe eliminated single delivery failed cold chain business reinvent expanding fulfilment rate internationally opening new markets today rangel successful international group partnership based trust employees learned october met adriano treve general collaboration roche made us number one manager roche portugal time needed distributor pharmaceutical products portugal distributor transport sensitive oncology products supplying million lifesaving products year completely honest told experience pharmaceuticals willing chairman training son nuno take invest learn trust retire greatest wish keep asked looked eye replied rangel group family continue fulfilling putting reputation reputation promise future company line make promises keep roche corporate governance corporate governance roche cor porate gove r nance roche corporate governance corporate governance roche principles board directors roche committed serving stakeholders corporate governance requirements particular th annual general meeting agm board directors corporate executive basis successful implementation applicable laws swiss stock exchange roche holding ltd march shareholders committee commitment corporate governance principles six swiss exchange directives swiss code reelected dr christoph franz chairman accordingly put focus business activities best practice corporate governance promulgated board directors march forthcoming agm board sustainable value creation innovation prescribe swiss business federation economiesuisse directors nominates chairman remaining management culture conforming recognised companys internal governance framework particularly furthermore agm reelected andr hoffmann members board directors reelection standards good corporate governance policy articles incorporation bylaws embodies prof dr pius baschera prof sir john bell paul bulcke transparent communication principles needed ensure companys prof dr richard p lifton dr andreas oeri prof dr pius baschera member businesses managed supervised manner bernard poussot dr severin schwan peter r voser board directors since decided stand strong board directors represents consistent good corporate governance including elected julie brown dr claudia sssmuth reelection announced december interests shareholders stakeholders necessary checks balances dyckerhoff new members board directors highly skilled managers act integrity term one year provided articles board nominates anita hauser election new extremely important printed annual report contains selected links incorporation dame deanne julius member board directors agm roche website wwwrochecom readers thus prof dr beatrice weder di mauro stand th consecutive year roche provided snapshot company reelection moreover board directors nominates recognised dow jones sustainability indices reporting date also directed sources dr christoph franz andr hoffmann group leader sustainability within consult time uptodate addition agm elected dr christoph franz prof dr richard p lifton bernard poussot pharmaceuticals biotechnology life sciences information corporate governance roche andr hoffmann prof dr richard p lifton peter r voser reelection members industry sustainability core business whereas annual report covers single financial bernard poussot peter r voser members remuneration committee agm practices award reflects commitment year ending december website contains remuneration committee running business way ethical information permanent nature well previous year board directors responsible creates longterm value stakeholders latest roche news companys articles organising meeting immediately following nominates bdo ag independent proxy incorporation bylaws curricula vitae agm board directors determined period conclusion corporate governance report sets members board directors corporate structure composition remaining committees ordinary annual general meeting shareholders structures processes rules roche takes executive committee published website shown see also pages election agm basis wellfunctioning corporate governance roche complies relevant details please refer following report composition name year birth first elected board directors dr christoph franz c e chairman andr hoffmann representative c e vicechairman annual general meeting annual general meeting shareholder group pooled voting rights dr andreas oeri representative e board directors shareholder group pooled voting rights prof dr pius baschera e board directors board committees prof sir john irving bell b e julie brown b e presidium nomination committee board committees paul bulcke b e remuneration committee prof dr richard p lifton c e audit committee bernard poussot c e corporate governance sustainability committee dr severin schwan f dr claudia sssmuth dyckerhoff b e corporate executive corporate executive committee peter r voser c e ceo ceo general committee ceo cfo hr secretary dr gottlieb keller pharmaceuticals diagnostics counsel board directors enlarged corporate executive committee honorary chairman dr fritz gerber enlarged corporate gred pred partnering communications board directors executive committee chugai corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson rochecomgovernance roche corporate governance corporate governance roche corporate executive committee group structure shareholders silvia ayyoubi head group human resources memberships corporate executive roches operating businesses organised note financial statements roche roche member corporate executive committee remained unchanged two divisions pharmaceuticals diagnostics holding ltd significant shareholders committee retired roche march pharmaceuticals division comprises two business addition significant shareholders published six exchange board directors appointed cristina wilbur information member corporate segments roche pharmaceuticals chugai whereas relevant webpage disclosure office six regulation succeed silvia ayyoubi head group human executive committee enlarged corporate genentech former third segment exchange regulation sixexchange resources member corporate executive executive committee listed see also pages integrated roche pharmaceuticals diagnostics regulationcom committee board directors corporate division consists following four business areas andr hoffmann vicechairman board significant executive committee diabetes care molecular diagnostics professional directors chairman remuneration shareholders diagnostics tissue diagnostics committee dr andreas oeri member board directors chairman boards composition name year birth position since business activities carried group corporate governance sustainability committee corporate executive dr severin schwan ceo roche group subsidiaries associated companies detailed serve respective capacities board committee daniel oday ceo roche pharmaceuticals information roche holding ltd significant committees representatives shareholder roland diggelmann ceo roche diagnostics subsidiaries associated companies including group pooled voting rights receive dr alan hippe chief financial officer company name listing information domicile share remuneration set forth remuneration report cristina wilbur head group human resources capital equity interest listed finance finance report note dr gottlieb keller general counsel report note roche group consolidated roche group consolidated financial statements enlarged corporate osamu nagayama chairman ceo chugai financial statements subsidiaries associates related parties exception executive committee dr michael varney head genentech research dr jrg duschmal works postdoc roche early development gred relationships exist shareholders prof dr john c reed head roche pharma research major shareholders listed finance report pooled voting rights early development pred notes roche group consolidated dr stephan feldhaus head group communications financial statements equity attributable roche crossshareholdings dr sophie kornowskibonnet head roche partnering shareholders related parties pages secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris roche pharmaceuticals incl genentech pharmaceuticals ian starkey since chugai chief compliance officer dr urs jaisli professional diagnostics molecular diagnostics diagnostics tissue diagnostics diabetes care composition corporate executive corporate executive committee ceo ceo general committee ceo cfo hr pharmaceuticals diagnostics counsel enlarged corporate executive committee enlarged corporate gred pred partnering communications executive committee chugai roche corporate governance corporate governance roche capital structure board directors corporate executive committee information roches capital structure provided including provisions protecting interests finance report notes financial statements nes holders described articles roche holding ltd additional details incorporation roche holding ltd information member board directors capacity group subsidiary three contained articles incorporation roche member corporate executive financial years preceeding current reporting holding ltd information debt instruments committee listed pages members period lack existing business issued outstanding bonds provided board directors age limit restriction connections group subsidiary independent movement recognised amounts last finance report note roche group term office curricula vitae current independence definition based definition three financial years detailed finance consolidated financial statements debt former members last five years swiss code best practice corporate report notes financial statements roche bodies information including information governance economiesuisse holding ltd information employee stock options provided years first election board members finance report note roche group additional positions memberships activities principles governance principles delegation company share capital chf consolidated financial statements equity available continuously updated internet competence reservation powers management divided fully paid bearer shares compensation plans including detailed group companies executive bodies nominal value chf information stocksettled stock appreciation rules pursuant article para point vegv company include economic environmental restrictions exercise voting rights rights ssars plan roche restricted stock number permitted activities board social topics principles together internal shares upon deposit shares voted unit plan roche performance share plan directors corporate executive committee organisation board directors division without restrictions roche connect roche option plan members outlined articles authority responsibilities board incorporation roche holding ltd management remits board committees authorised conditional capital roche issued options apart employee information control mechanisms available stock options described finance report since annual general meeting elects board dealings corporate management addition nonvoting equity securities note roche group consolidated financial members board directors chairman governed bylaws nes issued bearer form statements equity compensation plans board directors members form part share capital confer voting options issued connection debt instruments remuneration committee annual basis board directors roche holding ltd rights nes confers rights one elections nominee voted separately organised ensure group conducts share participate available earnings neither options awarded employees see articles incorporation roche businesses responsibly focus longterm liquidation proceeds following repayment share debt instruments issued holding ltd minutes th annual value creation end roche board capital roches nes rights pertaining thereto effect roches share capital general meeting roche holding ltd held delegated certain responsibilities several committees march composition chairpersons december described committees exception dr severin schwan none authorities responsibilities defined detail members board directors office bylaws board directors end member roches corporate executive committee served executive committees chaired independent directors board directors board directors board committees presidium nomination committee board committees rochecomarticleofincorporation remuneration committee rochecomboardofdirectors rochecomexecutivecommittee audit committee rochecomarticleofincorporation corporate governance sustainability committee rochecomannualgeneralmeetings rochecomarticleofincorporation corporate executive corporate executive committee rochecomcommittees committee rochecomarticleofincorporation roche corporate governance corporate governance roche according bylaws board directors auditors findings presented audit safety health environmental protection board directors met meetings board meeting may convened without chairman committee full board department generally hours length including present request members roche details risk management including risk corporate sustainability committee fullday meeting addition day visit board meets year assess chairmans factors risk management policy see science ethics advisory group seag major subsidiary board committees met performance meeting attended risk management website financial risk issues relating genetics genetic engineering follows chairman chaired vicechairman management specifically described presidium board directorsnomination finance report members corporate executive committee committee meetings approx hours part management information system mis system internal controls financial reporting invited attend meetings board remuneration committee meetings approx board directors informed see pages finance report directors report person agenda hours important issues sales performance etc monthly internal audit items concerning situation warrants audit committee meetings approx hours basis board access electronic information group audit reports general counsel members enlarged corporate executive platform provides timely information direct access gives regular briefings audit committee may also invited attend board corporate governance sustainability board directors boards committees committee corporate governance committees invite chairman board committee meetings approx hours system controls set forth sustainability committee ongoing activities corporate executive committee members deliver audit reports chief audit risk advisory reports committee meetings may elect board directors regularly conducts board directors established system executive attends audit committee partly commission independent expert reports call assessment selfassessmentassessment third parties controls continuously monitored corporate governance sustainability services consultants via electronical survey personal interviews audit committee corporate governance committee meetings external auditors performance selfassessment board sustainability committee board year several blackout periods imposed directors conducted directors consists following elements group audit independent appraisal function senior employees prohibited report operating financial risks risk evaluates reviews groups activities trading company stock following blackout members corporate executive committee management system service management annual audit plan periods effect maximum ordinary notice period twelve months roche group established risk management yearly defined focus areas eg market access third december february changeofcontrol clauses process covering entire company system party management validated senior management april april employment contracts place identify manage type risks presented audit committee roche june july potentially affecting business including economic group committed maintaining high standard october october management contracts fall within environmental social impacts risks internal control throughout worldwide operations blackout periods changed chairman scope subsection annex six directive opportunities containing stakeholder input management responsible assessing board directors circumstances warrant information relating corporate governance board directors highest governance business risks aspects operation body involved roches risk management policy sets implementing effective efficient processes approach accompanying responsibilities controls whilst ensuring compliance internal pharmaceuticals diagnostics divisions external rules regulations global functions conduct formal risk assessment conducting operational audits group audit process least year must develop risk determines managements response risks plans material risks surrounding business processes systems monitored deviations reviewed regular evaluates appropriateness completeness performance dialogues consolidated group risk efficiency processes controls action plans report including target risk profile discussed implement necessary changes enhancements corporate executive committee approved developed together businessauditee together group business plan material tracked completion risks reviewed board yearly basis statutory auditors see effectiveness risk management process chief compliance officer compliance officers monitored group risk advisory team subsidiaries see overall process regularly reviewed external rochecomriskmanagement rochecomenvironment additional information provided finance report note roche group consolidated financial statements risk management rochecomsustainability rochecomethicalconflicts remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activities roche corporate governance corporate governance roche remuneration shareholdings loans board board committees attendance corporate presidium governance rules aol nomination remuneration audit sustainability details regarding remuneration shareholdings board committee committee committee committee loans content method determining content board cec number meetings compensation shareholding programmes rules principles ch franz basic principles elements compensation applicable performance hoffmann shareholding programmes serving former related pay p baschera members board directors corporate rules principles j bell executive committee together description allocation equity securities j brown since march authorities procedure determining convertible rights options p bulcke set forth separate remuneration report additional amount payments rp lifton pages finance report notes members executive b poussot roche group consolidated financial committee appointed schwan statements equity attributable roche shareholders vote pay general oeri related parties pages listed meeting shareholders c sssmuth dyckerhoff note financial statements roche rules loans credit facilities since march holding ltd board executive shareholdings postemployment benefits p r voser rules vote pay retired board members agm retired march following rules remuneration shareholdings julius loans board directors board b weder di mauro corporate executive committee cec set forth articles incorporation aoi member committee invited guest board committee meetings participatory rights shareholders dr andreas oeri chairman corporate governance sustainability committee participatory rights shareholders articles incorporation defined roches articles incorporation shareholders representing shares nominal roche shares issued bearer value least chf million request restrictions admission annual general placement items agenda annual meetings exception shares must general meeting must done later deposited within specified period date days date meeting meeting admittance card must issued shareholders name provided rules issue instructions articles incorporation shareholder elect independent proxy rules electronic represented third party annual participation agm laid general meeting corresponding invitation agm regulated articles incorporation articles incorporation contain restrictions exercise voting rights quorum requirements stipulated conformity swiss code obligations rochecomarticleofincorporation roche corporate governance corporate governance roche change control defensive measures statutory auditors elected year services include advice relating process annual general meeting improvements regulations trainings articles incorporation contain provisions would terminated event acquisition auditing services provided legally required company formal policy governing mandatory bid rule swiss law applies vesting period restrictions preexisting awards engagement statutory auditor nonaudit would removed options could auditrelated services include assurance services policy prohibits certain services changeofcontrol clauses exercised immediately accounting services provided auditors provided permits certain services components remuneration based roche nes necessarily provided statutory auditor limits agreed audit committee services include audits pension funds potential nonaudit service engagement reviewed employee benefit plans internal control reviews policy authority proceed go beyond legal requirements given attestation services comfort letters consents relationship statutory auditors consultation tax services include services respect compliance tax returns tax advice except annual general meeting roche holding ltd reports statutory auditor consolidated services related audit tax march shareholders voted appoint financial statements financial statements kpmg ag kpmg statutory auditors based found pages respectively existing legal requirements swiss code years finance report obligations article concerning maximum relationship independent proxy term office seven years auditor charge kpmg received following remuneration ian starkey replaced predecessor john morris services statutory auditors roche holding ltd auditorincharge starting business year auditors roche companies information long auditors auditorin including chugai recent years bdo ag served independent rules issue instructions charge serving capacities provided proxy annual general meeting independent proxy rules electronic statutory auditors participate march shareholders elected bdo ag participation agm laid audit committee meetings prepare written millions chf independent proxy period corresponding invitation agm oral reports results audits audit auditing services conclusion ordinary annual general regulated articles incorporation committee oversees assesses auditors auditrelated services meeting shareholders bdo ag paid makes recommendations board information assurance services according expenditure totalling authorities responsibilities audit non statutory audits chf chf committee see article bylaws tax services statutory auditors participated meetings services audit committee total rochecomarticleofincorporation roche corporate governance corporate governance roche information policy chief compliance officer compliance officers network provided articles incorporation relevant information documents including corporate notices published swiss official media releases investor updates presentations gazette commerce daily newspapers analyst investor conferences available chief compliance officer compliance furthermore serve platform ideas designated board directors basler zeitung internet publications available officers network committed ensuring suggestions concerning documents finanz und wirtschaft lagefi le temps neue rochecompublications ordered roche group code conduct consistently zrcher zeitung email fax complied throughout roche group also addition roche established business ethics baselwarehouseservicesrochecom serves contact person shareholders employees incident reporting beir system enables roche reports halfyear fullyear results fax customers suppliers general public issues chief compliance officer capture track business reports published print andor online relating implementation compliance monitor alleged violations initial reports formats media events addition detailed contact address investor relations code employees parties local compliance officers resolution firstquarter nine months sales figures fhoffmannla roche ltd investor relations become aware violations roche group code published year april october group finance basel switzerland conduct bring attention business ethics incidents recorded system current list publication dates available tel managers supervisors local compliance local management receives specific english german internet fax officer report chief compliance officer concrete information alleged violation dr urs jaisli direct phone number roche group code conduct one certain pre additional information including details specific email ursjaislirochecom disclosures defined categories corporate governance contact persons available internet treated confidentially addition end sustainability committee audit committee employees may anonymously report irregularities board directors informed substantial complaints mother tongue via speakup violations managements corrective actions made line starting december new compliance tool group level socalled roche group code chief compliance officer reports general conduct help advice line introduced counsel also submits regular reports strives provide guidance case questions corporate governance sustainability committee uncertainties interpretation roche needed audit committee board group code conduct reference documents directors nonapplicabilitynegative disclosure expressly noted information contained provided six swiss exchange corporate mentioned herein either nonapplicable governance directive commentary thereto omission construed negative declaration rochecomarticleofincorporation rochecommedia rochecominvestors rochecominvestorscontacts rochecomcodeofconduct rochecomriskmanagement roche remuneration report remuneration report roche mune ration por material topic covered chapter executive compensation roche remuneration report remuneration report roche principles remuneration decision process approval framework roches success depends substantially expertise global company like roche marketcompetitive motivation performance employees remuneration plays key role along performance conviction forms basis compensation policy based transparent compensation structure ensure overview powers procedures making remuneration compensation packages competitive year remuneration committee roches decisions found bylaws roche aims remunerate employees fairly structure individual components regularly board directors decides remuneration roche board directors articles transparently line market conditions benchmarked swiss european international board members members groups incorporation also outlined enable participate appropriately criteria remuneration guidelines corporate executive committee terms sections principles governing specific companys success pursue goal providing underlying principles also subject regular longterm oriented performance share plan psp remuneration components see competitive performancebased resultsoriented outside comparisons awards decided annually board compensation directors acting upon recommendations since total aggregate amounts based however compensation policy one factor remuneration committee decisions submitted general strive balanced mix fixed variable safeguarding roches future success another key meeting approval implementing ordinance compensation components geared employees element corporate culture offers employees remuneration committee tracks market data excessive compensation listed corporations position management responsibility conditions make best possible salaries leading global pharmaceuticals verordnung gegen bermssige vergtungen bei contribution shared corporate goal improving companies major swiss companies brsenkotierten aktiengesellschaften vegv firstly variable components intended create healthcare patients includes sound value reports findings full board external general meeting shall vote annually binding additional financial incentives achieve corporate system based integrity courage passion consulting firm pricewaterhousecoopers pwc effect approval remuneration goals keep innovation consistently high time decentralised management assists remuneration committee roche board directors resolved board compensation level increasing value company approach plays major role wide scope performing market comparisons advising directors corporate executive committee policy creates stakeholder groups secondly order individual decisionmaking respectful interactions information remuneration committees remit details see rochecomrewards allow employees managers participate openness diversity wideranging training companys business success adequate compensation development opportunities attractive working sound value system measures key objectives incentivised environment unidimensional diminishment remuneration decision process approval framework rochecomliving annual bonus payments longterm sharebased questions remuneration would fall far short beneficiary ourvalues programmes remuneration board directors bod corporate executive decision approval roche committed fair performancebased components chairman c committee cec incl ceo roche group resultsoriented compensation policy links employees interests various base payremuneration stakeholder groups bonus c stocksettled stock appreciation rights remuneration committee restricted stock units since cec annual general replaced award meeting corresponding psps performance share plan board directors upon recommendation remuneration committee decisions pension c remuneration committee peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared abb actelion credit suisse lafargeholcim nestl sonova straumann swiss ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation roche remuneration report remuneration report roche peer set procedure submitting total board retrospective approval executive remuneration shareholder approval total aggregate bonus amounts corporate abbott laboratories abb annual general meeting executive committee chairman board abbvie actelion year annual general meeting agm directors financial year ended amgen credit suisse shareholders approve total remuneration submitted retrospectively ordinary agm astellas lafargeholcim board directors corporate executive separate binding approval astrazeneca nestl committee decided board directors roche bayer sonova remuneration committee board directors prospective approval bristolmyers squibb straumann respectively board executive aggregate remuneration eli lilly swiss submitted prospectively agm separate glaxosmithkline ubs according approval agm binding approval period two johnson johnson zurich insurance roche committed obtaining separate ordinary agms merck co binding shareholder approvals total peer set novartis remuneration paid board directors pfizer corporate executive committee follows sanofi takeda market comparison companies salary assessment approval total remuneration annual general financial year financial year meeting pharma peer set major swiss companies retrospective chairman bod c c bonus financial year total amount bonus corporate executive committee cec including ceo roche group cec bonus andr hoffmann chairman remuneration committee bonus financial year total amount prospective board directors bod including c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec including cec ceo roche group base pay aggregate total remuneration agm agm ssars psp base pay indirect benefits stocksettled stock appreciation rights ssars performance share plan psp indirect benefits agm agm agm roche remuneration report remuneration report roche remuneration components variable sti base salary bonus overview remuneration elements remuneration components linked indirect benefits employer contribution remuneration members board employees performance companys financial lti pensions insurance contributions directors corporate executive committee performance commercial success thus align stocksettled stock roche connect composed following elements concrete interests roche employees appreciation rights roche tax consulting services composition see chart composition shareholders performance share plan remuneration remuneration board directors expense allowances corporate executive committee lti remuneration components intended components others sustainably homogenously longterm oriented childrens schooling costs fixed base salary complemented align managements interest shareholders foreign tax obligation annual variable bonus shortterm incentive sti holders nonvoting equity securities give ahvivalv perennial variable remuneration elements participating managers additional incentive ssars psp longterm incentive lti achieve value growth form longterm total fixed shareholder returns creating value roche restricted stock units rsus remuneration investors management benefits well component corporate executive committee added longterm value created investors replaced awarding corresponding psps management penalised receiving less see base pay fixed individual performance objectives members base pay cash payment determined corporate executive committee position based salary market data leading composition remuneration board directors corporate executive committee global pharmaceuticals companies see footnote december end reporting year major swiss companies see footnote january following reporting year remuneration annual remuneration elements description c bod ceo roche group cec reflects individuals abilities experience committee decides bonuses amounts base pay monthly payment quarterly performance time pay adjustments likewise payable chairman board members remuneration see payments linked individual performance take corporate executive committee respect bonus annual payment years years cash account prevailing market conditions current reporting year based performance see blocked shares blocked shares companys overall financial situation aforementioned objectives pensions etc see time remuneration committee also decides perennial remuneration committee makes reviews form bonuses awarded ie cash payments remuneration elements final decision individual base pay paid andor longterm blocked nonvoting equity securities stocksettled stock see chairman board directors members andor blocked shares appreciation rights corporate executive committee ssars remuneration members board stocksettled stock appreciation rights performance share see years variable plan psp blocked shares bonuses variable ssars entitle holders benefit financially bonuses annually awarded individual increase value roches nonvoting equity contributions value creation business year securities grant date exercise date meant incentive strive outstanding ssars granted vest together three results create new business opportunities years exercised within seven years bonus amounts linked group divisional grant date unexercised ssars lapse without core profits sales growth constant exchange rates compensation since fair value ssars operating profit capital charge opac based calculated grant date using trinomial core operating profit core earnings per share model american options details see nonvoting equity security nes growth constant exchange rates product development pipeline ssar awards corporate executive committee achievement measurable qualitative allocated individually remuneration individual functional performance objectives committees discretion addition around competitive reasons roche disclose employees received ssar awards roche remuneration report remuneration report roche restricted stock units variable finishing end year indirect benefits foundation supplementing occupational pension restricted stock units rsus contain rights three overlapping performance cycles psp shown ceo roche group benefits insurances roche connect see receive nonvoting equity securities andor shares psp psp chairman respectively members payments foreign tax obligation tax threeyear vesting period plus value psp closed december corporate executive committee additionally consulting services annual expense allowances adjustment amount equivalent psp cycle none targeted nes received indirect benefits payments pension shown individual members sum dividend paid vesting period awarded psp per december funds mgb stiftung der f hoffmannla roche ag corporate executive committee received payments attributable number nonvoting equity targeted nes awarded psp fr mitarbeitergewinnbeteiligung als ergnzung schooling costs children securities individual award per december targeted nes der beruflichen vorsorge ie employee profitsharing granted rsu awards allocated individually awarded remuneration committees discretion weighting fixedvariable remuneration components target percentage total remuneration vested recipient three years plans key performance metric award thereafter resulting nonvoting equity securities total shareholder return tsr calculated may remain blocked years threemonth moving average rate start chairman vesting blocking periods interests end performance cycle rsu recipients shall aligned companys payment performance share plan determined board directors longterm success commitment employees board directors annual basis acting corporate executive company shall increased upon recommendations remuneration committee including ceo committee roche group rsus remuneration component corporate executive committee replaced starting psp awards remuneration awarding corresponding psps therefore component reserved corporate executive fixed variable variable longterm incentive programmes committee enlarged corporate executive corporate executive committee comprise psp committee whilst previous years members ratio variable remuneration components relative fixed base pay corporate executive awards ssars approximately senior management participated performance committee share plan structure lti simplified ratio variable remuneration components bonuses ssars psp relative value fixed base pay comparison competitors companys long longterm incentive programmes term performance mirrored share previous psp participants comprise sti lti price total shareholder return tsr shall ssars rsus awards approximately criteria bonus ssars psp stronger reflected corporate executive individual target value committees remuneration minimum psp historical performance maximum rsus remuneration component continued award originally targeted nes performance criteria group objectives group divisional value development value development around authorised roche business performance individual determined performance determined performance employees objectives considering core profits sales plus value adjustment plus value adjustment growth constant exchange rates dividends nes dividends nesbearer performance share plan psp variable operating profit capital charge opac grant shares grant psp established periods three based core operating profit core earnings group performance tsr years based threeyear comparison per share nonvoting equidity security relation tsr performance tsr peer companies see footnote nes growth constant exchange rates peer set tsr definition product development pipeline see respective year psp consists three split overlapping performance cycles new cycle group objectives na starting beginning year cycle b individual objectives na na applicable assessed consideration performance competitors macroeconomic development based annual base pay measured january first year cycle details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings roche remuneration report remuneration report roche remuneration board directors resolution approval amount remuneration members remuneration chairman board board directors directors members board directors members board directors decided remuneration committees received remuneration additional compensation discretion taking account market comparisons form quarterly fixed cash payments shown remuneration members board remuneration form cash payments directors table board annually tracked market data directors activities roche paid legally required employers pay leading global pharmaceuticals contributions total chf swiss social companies see footnote major swiss security programmes providing retirement disability companies see footnote assisted unemployment benefits ahvivalv consultancy pwc members board directors beside legally required contributions separately stated previous year board chairman board directors directors separately submit total aggregate bonus chairman board directors basic remuneration board directors general meeting financial year excluding chairman remained unchanged retrospectively binding approval since maximum amounts total aggregate exception chairman board remuneration board directors period directors bonus form blocked shares ordinary general meeting dr severin schwan executive member ordinary general meeting tabled board members board directors previous year general meetings awarded shares nonvoting equity securities prospectively binding approval see ssars loans credits granted members board directors capacity member chugai international council cic chugai pharmaceutical co ltd andr hoffmann received honoraria amounting total usd chf list members positions committee memberships chairmanships see detidua remuneration members board directors chf additional compensation additional special basic remuneration committee memberschairs compensation total remuneration ch franz chairman see total remuneration paid chairman board directors ahoffmann vicechairman see pbaschera jbell jbrown since march pbulcke rp lifton aoeri bpoussot sschwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee csssmuth dyckerhoff since march pr voser djulius retired march bweder di mauro retired march total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration paid period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part compensation detiduaroche remuneration report remuneration report roche detidua total remuneration paid chairman form bearer shares blocked years payable board directors april put shareholder binding vote chairman dr christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowances total form shares blocked years calculation number shares based share price date transfer april respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively ncluding employer contribution social securities beneficial parts gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits additionally employer contribution ahvivalv chf paid form part compensation detidua total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration including bonuses submission chairmans total aggregate totalling chf chf bonus binding vote annual general excluding additional employers contribution paid meeting ahvivalv totalling chf remuneration chairman board chf form part compensation directors includes bonus award chf form shares blocked years shown remuneration paid former members table total remuneration paid chairman board directors board directors board former member board directors dr franz directors submit remuneration committees bhumer received honoraria amounting bonus proposal adopted late chairman total usd chf serving board dr christoph franz respect member board directors member financial year payable april excluding chugai international council cic chugai legally required employers contributions ahviv pharmaceutical co ltd alv shareholder binding vote ordinary annual general meeting agm former member board directors william burns received honoraria amounting total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration paid detidua remuneration members board directors chf additional compensation additional special basic remuneration committee memberschairs compensation total remuneration ch franz chairman see total remuneration paid chairman board directors ahoffmann vicechairman pbaschera jbell pbulcke djulius rp lifton aoeri bpoussot sschwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee pr voser bweder di mauro total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december additionally employer contribution ahvivalv totalling chf including chairman paid form part compensation retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based share price date transfer april april respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively includes dr franz b humers bonus former chairman submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder vote receives function ceo roche board directors proposes group member corporate executive ordinary agm approve board remuneration totalling committee included part chf excluding legally corporate executive committees total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agmroche remuneration report remuneration report roche prospective approvals boards total aggregate future remuneration chf security holdings shares nes proposal agm agm agm december december aggregate amount aggregate amount aggregate amount close relatives close relatives security security period period period shares nes holdings others shares nes holdings others agm agm agm agm agm agm number number numbertype number number number numbertype number total aggregate amount proposal approval board directors approved agm ch franz hoffmann excluding legally required employers contributions ahvivalv excluding bonuses p baschera j bell j brown na na na na reconciliation reported remuneration comparison ordinary agm p bulcke shareholders approved remuneration ordinary agm actual remuneration amounted rp lifton members board directors chf excluding legally required employers oeri ordinary agm approved board remuneration contributions ahvivalv excluding bonuses b poussot totalling chf excluding schwan see security holdings see security holdings legally required employers contributions ahviv corporate executive committee corporate executive committee alv excluding bonuses period ending c sssmuth dyckerhoff na na na na ordinary agm pr voser retired board members prospectively approved total remuneration members board directors comparison actual total retired march payments made chf julius na na na na b weder di mauro na na na na total remuneration total remuneration total remuneration period period period total agm agm agm agm agm agm na applicable maximum total remuneration approved agm shares held shareholder group pooled voting rights listed actual total remuneration paid calculation end period jointly hold close relative within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings statements related parties note directors andr hoffmann dr andreas oeri financial statements roche holding ltd members founders families significant shareholders addition closely associated belong contractually december december bound shareholder group pooled voting rights respectively members board directors end group held shares persons closely associated held shares issued shares detailed information nonvoting equity securities nes shown group found finance report table security holdings note roche group consolidated financial roche remuneration report remuneration report roche remuneration corporate highest total remuneration paid dr severin schwan member corporate executive committee chf executive committee base salary ssars resolution approval remuneration committee board rsus restricted stock units remuneration members corporate directors outlined pages remuneration pension fundsmgb insurances executive committee decided decision process approval framework roche connect remuneration committees discretion taking subtotal account market comparisons members corporate executive bonus subject approval total aggregate bonuses corporate executive committee committee received remuneration work annual general meeting previous year board directors shown amount remuneration blocked nonvoting equity securitiesshares separately submit total aggregate bonuses ceo roche group dr severin schwan psp corporate executive committee general explained detail payments expense allowancefor tax consulting services meeting financial year retrospectively total binding approval highest total remuneration paid dr severin c alculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market schwan member corporate executive value maximum amounts total aggregate committee including employer contribution social securities beneficial parts detailed calculation remuneration see annual report remuneration corporate executive committee dr severin schwan executive member board number ssars grant value according trinomial model american call options chf trinomial model american call period ordinary general meeting directors received remuneration primary options value described stocksettled stock appreciation rights ssars members corporate executive committee ordinary general meeting function ceo roche group reflected number ssars grant value according trinomial model american call options chf trinomial model american call tabled previous year general highest total remuneration paid member options value described stocksettled stock appreciation rights ssars members corporate executive committee meetings prospectively binding approval see corporate executive committee see since members corporate executive committee receive rsus anymore replaced awarding corresponding psps included total amount paid corporate number rsus grant value chf nes closing price grant date march per rsu gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational amount remuneration members executive committee see total remuneration pension benefits corporate executive committee paid members corporate executive shares blocked years calculation number shares based share price date transfer april approval agm general provisions assigning authority decisions committee target number bearer shares psp bearer shares multiplied per bearer share price averaged three months october corporate executive committee remuneration december prior start performance cycle chf bearer share target number bearer shares psp bearer shares multiplied per bearer share price averaged three months october december prior start performance cycle chf bearer share includes annual expense allowance chf payments tax consulting services chf chf additionally employer contribution ahvivalv chf paid form part compensation detidua base pay chf r diggelmann hippe g keller oday c wilbur na ayyoubi retired corporate executive committee march total na applicable base pay including prorated remuneration period march december member corporate executive committee detidua base pay members corporate executive committeeroche remuneration report remuneration report roche bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting r diggelmann hippe g keller oday c wilbur na ayyoubi retired corporate executive committee march total na applicable prorated remuneration period march december detidua bonuses members corporate except dr severin schwan members stocksettled stock appreciation rights ssars chf executive committee corporate executive committee receive ssars ssars remuneration committee board directors bonus cash payment due determined corporate executive committee april dr severin schwan receive r diggelmann members bonuses based performance bonus form roche shares blocked hippe agreed objectives total aggregate years bonus payment due april g keller amount bonuses brought forward see oday binding vote annual general meeting c wilbur na ayyoubi retired corporate executive committee march total na applicable grant ssars grant value chf per ssars price chf expiry date stocksettled stock appreciation rights fair value ssars calculated ssars members corporate grant date using trinomial model american executive committee options trinomial model effective method ssars shown ssars table valuation american call options considers entitle holders benefit financially possibility exercising option time prior increase value roches nonvoting equity maturity called american option compared securities nes grant date european option allows exercise exercise date strike price ssars maturity date terms multiyear plan closing price roche nes grant date ssars vest three years numbers ssars strike prices expiry dates grant date vested ssars exercised grant values ssars shown converted nes within seven years grant ssars table numbers ssars date unexercised ssars lapse without compensation calculated time issue entered values table pages detidua restricted stock units members awards allocated individually remuneration corporate executive committee committees discretion vested restricted stock units rsusrights receive recipient three years thereafter resulting nonvoting equity securities threeyear vesting nonvoting equity securities may remain blocked period plus value adjustment amount years equivalent sum dividend paid vesting period attributable number non rsus remuneration component voting equity securities individual award corporate executive committee replaced grantedwere introduced new awarding corresponding psps therefore remuneration component partially replacing ssars variable longterm incentive programmes value ssar awards reduced corporate executive committee comprise psp awards balance awarded form rsus rsu ssars approximately restricted stock units rsus number value chf number value chf r diggelmann hippe since corporate g keller executive committee oday replaced award c wilbur corresponding psps na na ayyoubi retired corporate executive committee march total na applicable calculation value consideration reduction value due additional blocking period years reduced market value calculation value consideration reduction value due additional blocking period years reduced market value calculation value number rsus multiplied grant value chf nes closing price grant date march per rsu information trinomial model american options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf see strike prices table ssars detidua performance share plan psp senior management participated performance members corporate executive committee share plan starting psp awards remuneration component reserved corporate executive psp consists overlapping threeyear committee enlarged corporate executive performance cycles new cycle beginning committee previous years members year thus three cycles progressroche remuneration report remuneration report roche psp psp securities bearer shares individual performance share plan psp whereas psp closed december award granted requires roche none targeted nes awarded psp securities perform well better fair value grant fair value grant per december targeted nes peer set event investment per bearer share per bearer share awarded psp per december roche securities underperforms average return bearer share bearer share prices averaged prices averaged targeted nes awarded historical delivered peer companies fewer nes three three psp performance see bearer shares awarded months october months october december december prior fair value prior fair value provisions plan number bearer shares reserved plan target number start target number target number start target number bearer shares performance cycle bearer shares bearer shares performance cycle bearer shares nonvoting equity securities nes bearer shares members corporate executive committee psp psp psp psp psp psp reserved participants cycle shown table number value chf value chf number value chf value chf number securities actually awarded depend board directors decide actual level r diggelmann whether extent investment roche nes bearer shares cash equivalent awards hippe securities shares nes outperforms average psp cycles ga keller return investment securities issued peer close financial years respectively oday set peer companies comparisons based aim psp provide incentive c wilbur na na na securities market prices dividend yields ie participants achieve longterm value growth ayyoubi total shareholder return tsr reduce total effect shortterm market fluctuations security prices end psp cycle based na applicable averaged three months october threemonth average distributed dividends calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market december prior start performance cycle totalling chf billion chf billion value retired corporate executive committee march three months october december chf billion chf billion end cycle according terms plan participants received none originally targeted nes roche securities perform better average peer set board directors elect increase first time rsus corporate nes bearer shares award maximum award executive committee replaced awarding double originallevel reserved target number corresponding psps therefore longterm incentive nes bearer shares according psp plan plus programmes corporate executive committee value adjustment amount equivalent comprise psp ssar awards approximately sum dividend paid vesting period attributable number nonvoting equity detidua indirect benefits members roche connect voluntary stock purchase plan corporate executive committee offering employees opportunity buy roche employer contributions made social nonvoting equity securities nes amount security schemes pension plans groupwide equal annual salary discount employee stock purchase plan roche connect nes purchased plan subject respect members corporate executive holding period four years switzerland committee shown indirect benefits employer contributions table addition members corporate executive employer contributions shown table committee received annual expense allowances members payments foreign tax obligations tax consulting services shown table see footnote roche remuneration report remuneration report roche indirect benefits employer contributions chf pension payments pension payments funds annual taxtax funds annual taxtax mgb expense roche consulting mgb expense roche consulting insurances allowances connect services insurances allowances connect services r diggelmann hippe g keller oday c wilbur na na na na ayyoubi total na applicable including employer contribution social securities beneficial parts r etired corporate executive committee march mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits detidua remuneration loans members total remuneration paid members corporate executive committee corporate executive committee based contractual obligations roche paid calendar year members individual members corporate executive corporate executive committee received committee childrens schooling costs remuneration including bonuses totalling totalling chf chf chf chf excluding additional employers contribution paid ahviv aforementioned additional payments included alv totalling chf chf total remuneration members form part compensation corporate executive committee additional remuneration loans credits granted mentioned payments paid current former members corporate executive committee members corporate executive committee maximum regular period notice members executive remuneration subject approval corporate executive committee months annual general meeting changeofcontrol clauses employment contracts submission executive total aggregate bonuses binding vote annual remuneration former members general meeting corporate executive committee board directors proposes awarding members pensions totalling chf corporate executive committee bonuses chf paid former corporate dr severin schwan form roche shares executive committee members blocked years members corporate executive committee cash payment see totalling chf respect financial year chf excluding legally required employers contributions ahvivalv submit proposed total amount ordinary annual general meeting agm binding vote detidua detidua detidua detidua retrospective approvals members executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv submission executive total future aggregate incentives ssars calculated grant value without remuneration binding shareholder vote considering reductions value due blocking board directors proposes periods applicable psp calculated time ordinary agm approves remuneration reservation nonvoting equity securities shares corporate executive committee totalling taking account maximal potential chf excluding legally required double without considering reductions value due employers contributions ahvivalv blocking periods contributions pension benefits excluding bonuses period ending excluding legally required employers contributions ordinary agm ahviv alv well contributions expenses payments foreign tax obligations tax consulting amount executive total future aggregate services roche connect remuneration composed base pay longterm prospective approvals members executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration excluding bonuses period ending shareholders prospectively approved ordinary agm remuneration members corporate executive committee comparison ordinary agm ordinary ordinary agm approved remuneration agm remuneration amounted chf corporate executive committee totalling excluding legally required employers contributions chf excluding legally required ahvivalv excluding bonuses psp employers contributions ahvivalv assumption maximum valueroche remuneration report remuneration report roche prospectively approved total remuneration members executive committee comparison total shares nonvoting equity securities nes remuneration chf december december total remuneration total remuneration total remuneration close relatives close relatives period period period shares nes security holdings shares nes security holdings agm agm agm agm agm agm number number numbertype number number numbertype maximum total remuneration approved agm corporate executive committee total remuneration calculation end period schwan within approved limit calculation end period yes yes r diggelmann additional amount paid new members hippe corporate executive committee approval ga keller shares shares agm within approved total amount oday c wilbur na na na excluding legally required employers contributions ahvivalv excluding bonuses due award nes psp cycle originally included calculation maximum possible award amount ayyoubi na na na total remuneration period agm agm reduced chf total shares shares na applicable retired corporate executive committee march clawback according regulations psp programme addition applicable statutory provisions originally targeted awarded nes shares roches longterm incentive plans include option shall lapse without compensation upon notice ssars partially reclaim distributed compensation termination employment given reason result special circumstances clawback redundancy disability retirement number ssars held december employee voluntarily serves notice guidelines security holdings corporate executive committee termination employment ssars rsus board directors decided schwan unvested date termination employment ceo roche group cec members must r diggelmann lapse immediately without compensation acquire shares andor nes equivalent two annual hippe base salaries ceo roche group one annual g keller upon termination employment result base salary respectively end retain oday seriousmisconduct ssars rsus granted holdings long serve cec ca wilbur outstanding whether vested unvested shall lapse exception cristina wilbur joined total immediately without compensation according corporate executive committee ssars plan rules serious misconduct must fulfil requirement end price chf participant may include inter alia members corporate executive committee market price per nes activity leading serious disciplinary action fulfil requirement december chf repeated willful failure perform duties expiry date reasonably assigned roche security holdings grant value per ssar chf violation law public regulation december december since commission crime respectively members cec persons trinomial model american gross negligence willful misconduct closely associated held securities shown call options employment table shares nonvoting equity securities v alues according engaging conduct bringing disgrace disrepute nes ssars restricted stock units rsus corresponding annual reports roche andor subsidiaries violation roches directives guidelines relating business conduct type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary roche remuneration report statutory auditors report roche restricted stock units rsus number rsus held december corporate executive general meeting roche holding ltd basel committee schwan r diggelmann since corporate audited accompanying remuneration audit involves performing procedures obtain hippe executive committee report roche holding ltd year ended audit evidence disclosures made replaced award g keller december audit limited remuneration report regard compensation corresponding psps oday information according articles loans credits accordance articles ca wilbur ordinance excessive compensation stock ordinance procedures selected depend exchange listed companies ordinance contained auditors judgement including assessment total sections marked blue line including risks material misstatements remuneration grant value per rsu chf chf respective footnotes pages report whether due fraud error audit also nes closing price grant date nes average market price remuneration report includes evaluating reasonableness methods march days period prior grant date applied value components remuneration march well assessing overall presentation responsibility board directors remuneration report chf nes average market price board directors responsible days period prior grant date preparation overall fair presentation believe audit evidence obtained october remuneration report accordance swiss law sufficient appropriate provide basis ordinance board directors also opinion responsible designing remuneration system defining individual remuneration packages opinion opinion remuneration report auditors responsibility year ended december roche holding ltd responsibility express opinion complies swiss law articles accompanying remuneration report conducted ordinance audit accordance swiss auditing standards standards require comply ethical requirements plan perform audit obtain reasonable assurance whether remuneration report complies swiss law articles ordinance kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche independent assurance report independent assurance report roche perform assurance engagement obtain limited assurance inspection documentation analysis relevant identified sustainability information policies principles inspecting relevant documentation sample basis limited assurance engagement isae revised including roche group sustainability policies management substantially less scope reasonable assurance reporting structures documentation independent assurance report engagement relation risk assessment procedures inspecting principles roche materiality process including understanding internal control providing definition development adherence procedures performed response assessed risks gris environmental social economic reporting roche sustainability reporting consequently nature timing extent procedures requirements addressing soundness identification gathering sufficient appropriate evidence deliberately process determination impacted stakeholders peer limited relative reasonable assurance engagement competition review integration relevant regulatory corporate governance sustainability committee roche group internal sustainability reporting therefore less assurance obtained limited assurance requirements integration key organisational values roche holding ag basel guidelines based responsible care health safety engagement reasonable assurance engagement objectives report prioritisation material aspects environmental protection reporting guidelines published inspecting integration sustainability risks engaged perform assurance procedures european chemical industry council cefic procedures selected depend assurance opportunities group risk management process provide limited assurance aspects sustainability reporting guidelines g published practitioners judgement adherence internal guidelines sustainability reporting roche holding ag basel global reporting initiative gri assessment processes data consolidation consolidated subsidiaries roche included annual roche group internal corporate reporting manual independence quality control reviewing management ofand sustainability reporting report report version sustainability reporting guidanceeconomic complied independence ethical processes contributions people key figures performance requirements code ethics professional accountants assessing consolidation process data roche group level scope subject matter roche materiality determination process corporate issued international ethics standards board limited assurance engagement focused following level based sustainability reporting guidelines g accountants founded fundamental principles conducted work data outlined data information disclosed sustainability reporting published global reporting initiative gri integrity objectivity professional competence due care subject matter defined believe evidence roche year ended december defined guidelines people contributions confidentiality professional behaviour obtained sufficient appropriate provide basis management reporting processes respect key figures sustainability risks opportunities assurance conclusions sustainability reporting material aspects internally gathered collated aggregated firm applies international standard quality control preparation safety security health environmental accordingly maintains comprehensive system quality conclusion protection people key figures well related inherent limitations control including documented policies procedures regarding based work performed described report control environment relation data aggregation accuracy completeness sustainability indicators compliance ethical requirements professional standards identified roche sustainability reporting nothing come key figures subject inherent limitations given nature methods applicable legal regulatory requirements attention causing us believe material respects materiality determination process roche group level determining calculating estimating data roche group internal sustainability reporting guidelines according requirements gri g guidelines assurance report therefore read connection summary work performed based gri g sustainability reporting guidelines disclosed pages report roches internal guidelines definitions procedures assurance procedures included amongst others well cefic guidelines applied design sustainability risks opportunities reporting sustainability performance following work roche materiality determination process corporate determination process based roche corporatelevel evaluation application roche group guidelines level disclosed adhere principles guiding activities disclosed paragraph risk roches responsibilities reviewing application roche group internal factors eg soundness stakeholder determination peer review management report roche corporate governance sustainability committee corporate sustainability contributions guidelines relevance regulatory environment integration key people key figures disclosed pages report responsible subject matter criteria well site visits management inquiry organisational values objectives defined gri g key figures including greenhouse gas emissions selection preparation presentation selected visiting selected sites roches pharmaceuticals design sustainability risks opportunities scope scope resulting business travel information accordance criteria responsibility diagnostics divisions usa germany japan vietnam determination process corporate level disclosed compressed air liquid nitrogen waste generated includes design implementation maintenance related indonesia selection based quantitative function designed operations tables graphs pages internal control relevant reporting process free qualitative criteria internal reporting processes collect aggregate report material misstatement whether due fraud error interviewing personnel responsible internal sustainability people data functioning designed provide consolidated data information roche group reporting data collection sites visited appropriate basis disclosure level relation contributions breakdown disclosed responsibility roche group level determine understanding internal reporting processes collect aggregate pages report responsibility form independent opinion based application roches internal sustainability guidelines contributions data functioning designed provide limited assurance procedures whether anything come assessment key figures appropriate basis disclosure carried work data reported prior attention indicate identified sustainability performing tests sample basis evidence supporting sustainability information mentioned subject matter reporting periods performed work respect information selected contained report stated selected contributions people key figures ie roche disclosed within sustainability reporting roche projections targets material respects accordance reporting criteria accident rate energy consumption greenhouse gas emissions annual report stated accordance related energy consumption halogenated hydrocarbons reporting criteria criteria planned performed procedures accordance water waste contributions healthcare institutions patient management reporting processes respect international standard assurance engagements organisations public policy bodies philanthropic zurich january sustainability reporting key figures prepared isae revised assurance engagements audits organisations headcountfte data training hours pricewaterhousecoopers ag roche based internal policies procedures set reviews historical financial information standard concerning completeness accuracy adequacy consistency forth following requires comply ethical requirements plan christophe bourgoin bettina buomberger roche imprint imprint roche published cautionary statement regarding forwardlooking statement regarding earnings per share growth key dates fhoffmannla roche ltd statements profit forecast interpreted group communications annual report contains certain forwardlooking mean roches earnings earnings per share basel switzerland statements forwardlooking statements may subsequent period necessarily annual general meeting tel identified words believes expects match exceed historical published earnings march wwwrochecom anticipates projects intends seeks earnings per share roche estimates future similar expressions firstquarter sales orderdownload publications discussion among things strategy goals trademarks mentioned enjoy legal protection april internet rochecompublications plans intentions various factors may cause actual email baselwarehouseservicesrochecom results differ materially future links thirdparty pages provided convenience halfyear results fax reflected forwardlooking statements contained express opinion content july annual report among others pricing thirdparty pages expressly disclaim media relations product initiatives competitors legislative liability thirdparty information use nine months sales tel regulatory developments economic conditions october email rochemediarelationsrochecom delay inability obtaining regulatory approvals roche annual report published german bringing products market fluctuations english investor relations currency exchange rates general financial market tel conditions uncertainties discovery reporting consists actual annual report email investorrelationsrochecom development marketing new products new finance report contains annual uses existing products including without limitation financial statements consolidated financial corporate sustainability committee negative results clinical trials research projects statements regards content management tel unexpected side effects pipeline marketed report per articles incorporation consists email corporatesustainabilityrochecom products increased government pricing pressures aforementioned reports exception interruptions production loss inability remuneration report obtain adequate protection intellectual property rights litigation loss key executives printed nonchlorine bleached fsccertified paper employees adverse publicity news coverage believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochethe pictures submitted roche employeesfhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom roche annual report believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world roche